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Abstract  
The protein S100P has been associated with the aggressiveness of several 
neoplastic disease, including pancreatic ductal adenocarcinoma (PDAC). S100 
proteins are a family of calcium binding proteins that are small dimeric members of 
the EF-hand superfamily of Ca2+ binding proteins. In pancreatic ductal 
adenocarcinoma, protein S100P is overexpressed, and thereby meditate tumour 
growth, drug resistance and metastasis. Extracellular S100P binding to the cell 
surface receptor for advanced glycation end products (RAGE), triggers 
downstream signalling pathways and mediates cell growth and differentiation, cell 
cycle regulation and metabolic control. An effective treatment strategy would be to 
disrupt the formation of this S100P-RAGE complex by blocking the active binding 
site of S100P to the RAGE receptor. The aim of the present study was to 
investigate the interactions of drug compounds that are designed to block the 
S100P-RAGE complex formation. In order to perform this S100P protein was 
expressed in Escherichia. coli using a recombinant plasmid for wild type S100P 
and purified by affinity chromatography using a HisTrap column. The purity of the 
protein was assessed using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). The concentration of the purified protein was 
determined by either the Bradford assay or bicinchoninic acid assay (BCA). In this 
study, the interactions sites of the recombinant S100P with each of the compounds 
was assessed by nuclear magnetic resonance (NMR) spectroscopy. The 
interaction sites were modelled by a HADDOCK approach, using the interacting 
residues as constraints to model the structure. In conclusion the ligands C72, 
IBS409, IBS798 and IBS863 were identified to interact with S100P mainly in the 
hydrophobic pockets of the protein S100P. Binding sites of the ligands were 
identified via NMR, and the binding was found to be dominated by hydrophobic 
interactions. Further ITC experimentation may be required in order to gain an 
understanding of the stoichiometry and the binding affinity for these ligands. 
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1 Introduction  
1.1 Pancreatic ductal adenocarcinoma (PDAC) 
PDAC is one of the most common types of pancreatic cancer, where 85% of the 
cancerous tumours of the pancreas are adenocarcinomas(Dunne and Hezel 2015). 
There are approximately 8000 people in the UK diagnosed with pancreatic cancer in 
2011 while approximately equal amount of deaths in 2012 and an equal amount of 
deaths in 2012 (CRUK, 2015). It is understood that the cause of cancer is due to the 
mutation of a type of gene known as an oncogene, which gives the abnormal growth 
potential to cells. In more than 90% of PDAC, there is a mutationally activated 
oncogene known as K-ras. K-ras is a member of the RAS family of GTP-binding 
proteins mediating a range of cellular functions such as proliferation, differentiation, 
and cell survival through the various effector pathways, notably the mitogen-activated 
protein kinase (MAPK) (Dunne and Hezel 2015). Another type of genes known as 
tumour suppressor genes; the type of genes prevent the cancer growth, p53 gets 
inactivated in more than 50% of PDAC. The loss of activity of p53 can cause the p53 
dependent DNA damage checkpoint response to be skipped and thereby serves to 
enable the growth and survival of cells, with damaged DNA(Dunne and Hezel 2015). It 
is believed that more than one gene is responsible for the occurrence of cancers 
however the exact molecular mechanism of the development and the progression of 
PDAC by these genetic mutations is still incompletely understood(Dunne and Hezel 
2015). 
PDAC arises in the exocrine tissues of the pancreas, specifically in the cells of the 
ducts that carry digestive enzymes to the small intestine. PDAC is distinct from 
other cancers due to the biological barrier that it builds around itself as shown in 
the schematic representation in Figure 1(NCI, 2013). It has been demonstrated 
using mouse models that PDAC tumours are surrounded by a dense cellular matrix 
or stroma that shields the tumour mass (Figure 1). This increases the fluid pressure 
within the tumour microenvironment compressing existing blood vessels and limits 
the blood supply to the tumour (Grippo and Munshi, 2012).Consequently, on 
administration of a chemotherapy drug, the restricted blood flow prevents sufficient 
amounts of the drug from reaching the tumour. Inefficient drug delivery is one of 
the reasons for why PDAC does not respond to chemotherapy (NCI, 2013). In 
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addition, PDAC aggressively invades regional lymph nodes and the liver, and less 
often the lungs and visceral organs (Grippo and Munshi, 2012) 
 
.
  
Figure 1: The schematic representation of a pancreatic ductal adenocarcinoma. The figure 
illustrates the appearance of the collapsed blood vessels in the connective tissue surrounding 
the tumour. This causes restriction in the blood flow and inefficient drug delivery (National 
Cancer Institute, 2014) 
 
1.2 PDAC Screening and Treatment  
Presently there is no agreed screening test to identify or early diagnose pancreatic 
cancer. A physical examination of the signs of the disease such as lumps or 
anything unusual, together with a history of the patient’s health habits, past 
illnesses and treatments is the initial procedure. However the deep anatomic 
location of the pancreas makes it unlikely to detect small localised tumours by 
routine abdominal examination (NCI, 2015). The two main functions of the 
pancreas is to produce digestive juices (exocrine pancreas cells) and hormones 
(endocrine pancreas cells) such as insulin and glucagon, that aid in the control of 
blood sugar levels. Therefore unusual levels of substances such as blood sugar 
can be a sign of disease (NCI, 2015). 
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The best known blood marker is CA19-9, a “carbohydrate associated antigen” also 
known sialylated Lewis (a) antigen, which is elevated in pancreatic cancer. The 
principal limitation of using this biomarker is its frequent elevation in non-malignant 
conditions like pancreatitis and obstructive jaundice, and its inability to be detected 
at early stages of the malignancy. It is also unsuitable for about 5-10% of patients 
who lack the Lewis antigen (NCI, 2015)  
There are also specific DNA mutations that are found in pancreatic cancer in the 
well-known genes K-ras, p16, p21, p53, DPC4, and BRCA2 (Dowen et al. 2005). 
Recent studies using Affymetrix and cDNA micro-arrays have identified a number 
of differentially expressed genes in PDAC (Grutzmann, Pilarsky et al. 2004). These 
assays however have not yet been translated into screening tests or diagnostic 
markers. There are several other agents such as cell surface associated mucins 
(MUC), carcinoembryonic antigen (CEA), and heat shock proteins (HSP) which are 
studied as screening and diagnostic markers, however without much success (NCI, 
2015).  
Generally, the diagnosis of pancreatic cancer is difficult at an early stage due to 
non-specific symptoms such as loss-of-appetite, weight loss, abdominal discomfort 
and nausea. One of the common physical signs is jaundice with associated itching. 
Non-specific symptoms of pancreatic cancer causes delay of diagnosis at an early 
stage and thus the majority of patients (>80%) have tumours that are already 
locally at an advanced stage or metastatic upon diagnosis(He and Yuan 2014). At 
this stage of the disease, surgical resection of the tumour is not effective leaving 
such patients with a particularly bleak prognosis. Moreover, patients who undergo 
surgical treatment are still at risk due to the high rate of recurrence of the disease 
(He and Yuan 2014). 
There are no universally agreed guidelines for the medical treatment of patients 
with pancreatic cancer who are not candidates for surgery or who have recurrence 
of the cancer after surgical re-section (NCI, 2015). Surgical resection is currently 
the only potentially curative option for localised tumours. However, only 15-20 of 
individuals of the individuals with pancreatic cancer are eligible for surgery, as 
surgical resection of the tumour is only available to patients with localised tumours  
(He and Yuan 2014). The metastatic nature of PDAC along with its 
chemoresistance, leads to the disease being one of the most lethal human cancers 
having a 5-year survival of less than 5% (Dakhel, Padilla et al. 2014).  
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Treatment of PDAC therefore remains a major challenge in oncology, as the PDAC 
has a general resistance to chemotherapeutic approaches. This indicates the 
importance of finding new biological targets that chemotherapeutic treatment is 
effective. The chemotherapy agent 5-FU (fluorouracil) has been used in the 
medical treatment of pancreatic cancer patients. Fluorouracil acts as an inhibitor of 
thymidylate synthase, which is an enzyme that is critical factor in the synthesis of 
pyrimidine (a building block of the DNA replication) thus affecting cell cycle 
progression (Giovannetti, Mey et al. 2006). The underlying effect of most treatment 
agents is by interfering normal cell cycle progression. These chemotherapeutic 
agents tend to affect most cells in the body, although the effect is severe on 
unstable rapidly growing cancer cells. Gemcitabine has been used as a drug for 
treatment of pancreatic cancer, however it offers meagre therapeutic benefit 
(Sedov and Poplin 2010). This has led to the search for novel therapeutic 
approaches for PDAC. 
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1.3 S100P: A Potential Therapeutic Target for Cancer  
S100P is a 95 amino acid member of the S100 subfamily that share the Ca2+ 
binding structural motif, EF-hand (Zhang, Wang et al. 2003). The protein was first 
purified from placenta, (Becker, Gerke et al. 1992) hence it was designated with a 
‘p’. The Figure 2 A below demonstrates the secondary structure of the S100P 
protein indicating the two α-helices that provide the Ca2+-binding site. The 
conformational changes that are introduced by calcium in the S100P protein, 
exposes a hydrophobic surface responsible for the binding of target proteins 
(Arumugam and Logsdon 2011). S100P monomer structure contains four helices: 
residues 3-18 (Helix-1), 30-40 (Helix-2), 53-61 (Helix-3) and 71-92 (Helix-4) 
(Zhang, Wang et al. 2003). (Figure 2 B) 
 
Figure 2: (A) The secondary structure of Ca2+ bound human S100P protein dimer, indicating the 
Ca2+ atoms in green. The alpha helices are in purple and the beta strands in yellow. (B) A 
representation of the S100P structure showing the two domains of the dimer. The helices are 
named as 1, 2 3 and 4 for each domain.  
A study by Logsdon et al. 2003 showed that the protein S100P is overexpressed in 
PDAC. Expression of S100P was indicated to be specific for pancreatic cancer 
cells and not found in chronic pancreatitis samples. The specificity of the 
expression of S100P in cancer cells suggests that it is a useful histological marker 
for cancer (Logsdon et al. 2003). A study by Crnogorac Jurcevic et al, 2003 also 
reported that the overexpression of S100P observed in several carcinomas 
including PDAC (Crnogorac-Jurcevic et al. 2003) Furthermore, S100P prompted 
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the progression of these cancer types and have specific roles in survival, cell 
proliferation, angiogenesis and metastasis. As reviewed here S100P, has been 
found to have dysregulated expression in PDAC; evidence suggest that it promotes 
tumour growth and metastasis. Therefore blocking S100P function might be a 
useful in improving the therapeutic responses to treatment 
 
1.4 Role of S100P in Pancreatic Ductal Adenocarcinoma 
One of the key molecular targets of S100 proteins in pancreatic cancer is the 
receptor for advanced glycation end products (RAGE) (Arumugam, Simeone et al. 
2004). RAGE is a member of the immunoglobulin protein family of cell surface 
molecules. The RAGE receptor is composed of an N-terminal V-type (variable) 
domain and two C-type (constant) domains. The ligand binding site of RAGE is 
reported to be on the V-type domain. RAGE binds to multiple proteins that are 
implicated in several diseases; including S100 calcium binding proteins such as: 
S100A12, S100A1, S100B, and S100P (Arumugam, Simeone et al. 2004). S100P 
acts through binding of the extracellular domain of RAGE, which triggers the 
cytoplasmic domain of RAGE to homodimerise and activate the downstream 
pathways involved in cell proliferation and survival as the MAPK and nuclear factor-
kappa B (NF-κB). The intracellular signalling mechanisms activated by RAGE is not 
completely understood.  
Figure 3 is a schematic representation of the signalling pathway proposed by 
Penumutchu, Chou and Yu, 2014b for the calcium-bound S100P-RAGE. The figure 
also demonstrates the extracellular, V domain and C domains of the RAGE 
receptor and also the cytoplasmic domains. In pancreatic cancer these pathways 
are constitutively active (Arumugam, Simeone et al. 2004). The overexpression of 
the S100P seen in PDAC, may meditate tumour growth metastasis. These effects 
can be blocked via agents that interfere with RAGE, indicating that the S100P can 
act in an autocrine manner with RAGE (Arumugam, Simeone et al. 2005). An 
effective strategy in the treatment of diseases caused by the overexpression of the 
S100P could be to prevent the formation of this S100P-RAGE complex.   
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Figure 3: Schematic representation of the signalling pathway proposed by Penumutchu, Chou 
and Yu, 2014b for the calcium-bound S100P-RAGE. The figure also demonstrates the 
extracellular, V domain and C domains of the RAGE receptor and also the cytoplasmic 
domains.  
Efforts to inhibit the interaction of S100P and RAGE had led to the identification of 
a number of specific molecules that interact with RAGE and block activation of the 
RAGE receptor. Several molecules have shown binding affinity towards S100P, 
including cytoskeletal ezrin. This protein interacts with S100P in a Ca2+ dependent 
manner and influences its ability to bind actin (Koltzscher, Neumann et al. 2003).  
S100P has shown interactions with CacyBP/SIP. This is a component of the novel 
ubiquitinylation pathway leading to β catenin degradation (Filipek, Jastrzebska et 
al. 2002). Although these molecules are shown to interact with S100P in vitro, it is 
not known whether there is an interaction in vivo or the effect the interactions have 
on cell function. Studies using mouse models have shown that anti-allergic drug 
cromolyn is able to interact with S100P and prevent the activation of RAGE. 
However, despite cromolyn being able to inhibit RAGE, it has been found that the 
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inhibition of RAGE is weak in human mast-cell secretion and cromolyn is also is 
poorly absorbed orally. Therefore, cromolyn has not been clinically tested for its 
benefits for use as a cancer drug. (Arumugam, Ramachandran et al. 2013) 
1.5 Aim and Objectives 
The purpose of this project was to identify lead compounds that can inhibit the 
interaction of the S100P with RAGE and may be beneficial as a cancer therapy. 
The potential candidate compounds developed by Dr. Rossiter and her team were 
tested for other effects on cellular function including proliferation and migration 
(Camara, Rossiter, Kholi, and Kirton, 2013). In order to perform this S100P protein 
was produced in Escherichia. coli by using a recombinant plasmid for wild type 
S100P (provided by the University of Liverpool). The S100P protein was then 
expressed and purified by affinity chromatography using a HisTrap column (GE Life 
Sciences). The purity of the protein was assessed using SDS PAGE and the yield 
of the purified protein was determined by either the Bradford or the BCA assay. 
The interactions sites of the recombinant S100P with each of the compounds were 
assessed by NMR spectroscopy and the interaction sites were modelled by a 
HADDOCK approach using the interaction sites as constraints to model the 
structure. Isothermal Titration Calorimetry (ITC) was used to study the binding 
affinity and the stoichiometry of the ligands that interacted with S100P.  
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2 Materials and Method  
2.1  Gene sequence and vector used for expression of S100P 
The S100P protein was expressed using a plasmid encoding wild type (WT) human 
S100P in pET28 vector including a hexa-histidine tag and a kanamycin resistance 
gene. This plasmid was provided by the University of Liverpool.  
A ProtParam analysis of the sequence of the plasmid (MGSSHHHHHH 
SSGLVPRGSH MTELETAMGM IIDVFSRYSG SEGSTQTLTK GELKVLMEKE 
LPGFLQSGKD KDAVDKLLKD LDANGDAQVD FSEFIVFVAA ITSACHKYFE KAGLK) 
indicated the molecular weight of the S100P protein to be 12,563.2 Da 
2.2  Transformation of plasmid to bacterial cells  
Transformation by heat shock is a basic technique which involves the insertion of a 
foreign plasmid into bacteria, in this case plasmid encoding WT S100P pET28 
vector into Escherichia coli strain BL21 Star. Initially the chemically competent 
bacterial cell mixture and plasmid DNA were defrosted on ice. 1µL of plasmid DNA 
was added to the competent bacterial cell vial and mixed by gentle rotating action 
of the pipette tip, and incubated for 15 minutes on ice. The vial was then placed on 
a heat block set at 42°C for 30 seconds and then re-placed on ice (heat shock). 
Approximately 600µL of sterile Super Optimal broth with catabolite repression 
(Tryptone 2% w/v, Yeast extract 0.5% w/v, NaCl 10mM, KCl 2.5mM, MgCl2 10mM, 
Glucose 20mM) was added to these transferred cells and were incubated at 37°C 
for 45 min with agitation.  
The transformed bacteria were plated on to Luria Bertani agar plates containing 
50µg/mL kanamycin (LB agar tablets by Sigma Aldrich) and incubated at 37°C 
overnight. A single colony was used to prepare a starter culture of E. coli bearing 
the S100P plasmid.  
 
2.3 Expression of recombinant S100P 
Initially a starter culture of E.coli strain BL21 Star cells (100mL) bearing the S100P 
plasmid was grown overnight at 37ºC in Luria broth medium containing 50µg/mL of 
- 21 - 
 
kanamycin. The overnight culture was pelleted at 5,000 rpm for 15 min, the pellets 
were then gently re-suspended in ~2ml of minimal media.  
Table 1: Recipe for 500mL of minimal growth medium and 500mL of Solution A (autoclaved). 
Minimal growth medium 
10X Solution A 50mL 
1 M MgSO4 (autoclaved) 500µL 
1 M CaCl2(autoclaved) 68 µL 
Thiamine solution (filter sterilized 0.22µm filter) 25 µL 
Glucose* 2g 
NH4Cl* 0.5g 
10X Solution A (autoclaved) 
KH2PO4 62.5g 
Na2HPO4 37.52g 
 
*For isotopic labelling 15NH4Cl was substituted for NH4Cl. The glucose and NH4Cl 
was dissolved thoroughly using a small amount of the solution and filter sterilised 
back in to the media using a 0.22 µL filter. Kanamycin (50µg/mL) was added in 
order to make sure that only bacterial cells with kanamycin resistance gene (i.e. 
bacterial cells containing the plasmid) will survive in the minimal growth media. 
The protein is produced by the expression of the plasmid which are grown on 
minimal medium supplemented with 15NH4Cl and wild-type (wt) glucose. This 
enables the protein to be labelled with 15N. In order to perform NMR, it is necessary 
that the S100P protein produced has a 15N label.  
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About 1mL of the dissolved pellet was added to the minimal medium prepared 
(500mL) by starting with an OD600 (optical density at 600nm) of ~0.100 for re-
suspended pellet. Transformed bacteria were grown to an OD600 of 0.6, and 
recombinant protein expression was then induced by adding Isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The cell culture was 
incubated overnight at 18°C in an agitating incubator at 200 rpm. After incubation, 
cells were harvested by centrifugation (4500 rpm; 20 min) and re-suspended in ~ 
30mL of lysis buffer (25 mM imidazole, 20 mM Tris, 500 mM NaCl, 2 mM 
dithiothreitol (DTT); pH 6.5) and stored at -20ºC until purification. 
2.4 Purification of recombinant S100P  
The cell suspension was defrosted and, to prevent proteolysis, an EDTA-free 
protease inhibitor (1 tablet dissolved in 2mL of water) was added. The cell 
suspension was then sonicated on ice (six 30 second periods at 25 W, with 30 
second breaks between the pulses) using a Bransson sonifier and centrifuged at 
high speed (15,000 rpm for 45 minutes a Beckman centrifuge). The supernatant 
obtained after high-speed centrifugation was filtered through a 0.22 µL filter. A 
sample of filtered lysate was taken for SDS PAGE analysis. The S100P protein 
encoded has a hexa-histidine tag. Histidine-tagged proteins have a high selective 
affinity for Ni2+ and several other metal ions that can be immobilized on a 
chromatographic media using chelating ligands. This chromatographic technique is 
known as immobilized metal ion affinity chromatography (IMAC) (Gelifesciences, 
2015). The protein purification was performed using a HisTrap High Performance 
5mL column volume (cv) (GE Healthcare). This Nickel Sepharose column 
contained 20% ethanol (storage conditions), therefore when setting up the column, 
it was washed out with 10 cv water then equilibrated with 10 cv of lysis buffer. The 
filtered lysate was then applied and the flow-through collected.  The column was 
washed again with 10 volumes of lysis buffer and flow-through collected. A sample 
of the flow-through collected was taken for SDS PAGE analysis. Wash buffer (100 
mM imidazole, 20 mM Tris, 500 mM NaCl, 2 mM DTT; pH 6.5) containing a higher 
concentration of imidazole than the lysis buffer was used to wash the column (10 
cv).  
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For the elution step, 5 cv of Elution Buffer 1(EB 1) (350 mM imidazole, 20 mM Tris, 
500 mM NaCl, 2 mM DTT; pH 6.5) was applied while collecting the flow-through in 
fractions. Fractions where collected until their absorbance at 280nm wavelength 
reached the baseline. A sample of each of the fractions was taken for SDS PAGE 
analysis.   
Finally 5 cv of Elution Buffer 2 (EB 2) (500 mM imidazole, 20 mM Tris, 500 mM 
NaCl, 2 mM DTT; pH 6.5) was applied. A concentration of 500 mM imidazole in the 
EB 2 ensures complete elution of the histidine-tagged protein. The flow-through 
was collected and a sample was taken for SDS PAGE analysis. The fractions with 
increasing absorbance readings where dialysed overnight at +4ºC in an 
appropriate buffer, depending on the method that the S100P expressed would be 
used for. The Figure 4 is a schematic representation of the general steps involved 
in the purification of histidine tagged proteins. 
 
Figure 4: Schematic representation of the general purification of histidine-tagged proteins 
(adapted from Gelifesciences, 2015) 
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2.5 SDS-PAGE 
Samples were obtained from each stage of the purification for SDS PAGE analysis 
in order determine if the protein was expressed in the bacteria and also to assess 
the purity of the sample. SDS-PAGE is one of the most common methods of PAGE 
for separation of proteins. In SDS-PAGE the samples are heated in SDS (anionic 
detergent) in the presence of a reducing agent such as DTT, which cleaves the di-
sulphide bonds and aid in the unfolding of the protein. SDS also coats the linear 
protein with a negative charge. Therefore during electrophoresis the separation of 
the protein depends on the molecular weight of the protein (Walker, 2002). A set of 
reference proteins known as molecular weight markers are run alongside the 
samples in order to provide a reference to which the molecular weight of the 
sample proteins could be compared to (Lifetechnologies, 2015). 
The samples collected from each of the stages of the protein purification was 
analysed by SDS PAGE. The  molecular weight marker (BIO-RAD broad range 
161-0317) used was also provided by the technical staff diluted in 2× SDS-PAGE 
sample buffer (supplied by technical staff-125 mM Tris-HCl, 20% glycerol, 4% SDS, 
0.04% bromophenol blue, 20 mM DTT) at a ratio 1:20. The samples were diluted in 
a 1:1 ratio with 2 × SDS-PAGE sample buffers and denatured at 95°C for 5 minutes 
along with the molecular weight markers. The analytes were separated alongside 
the molecular weight markers (MWM) on 15% polyacrylamide resolving gels.  
The SDS analysis will also show the fractions containing the most amount of 
protein, these fractions were dialysed overnight at +4ºC in relevant buffers 
(depending on the assays the protein will be used for). The S100P protein sample 
was then stored at +4ºC. The unused samples were snap frozen using liquid 
nitrogen and stored at -20ºC until used.  
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2.6 Bradford Assay 
The quantity of protein purified was determined by a standard chromogenic method 
known as the Bradford assay. This is a colorimetric assay based on the shift of the 
absorbance of the Coomassie Brilliant Blue G-250 dye. Under acidic conditions the 
dye changes from the red form to the blue form when protein bound. The bound 
form of the dye has a maximum absorbance of 595nm. Bovine serum albumin 
(BSA) standard solutions of concentrations ranging from 0-1.0 mg/mL were 
prepared and 100 µL of each standard solution was loaded into test tubes in 
duplicates. 100 µL of the purified protein solution was also added to test tubes in 
duplicates. 5 mL of Bradford Reagent (prepared by technical staff) was added to 
the 100 µL of each of the standard solutions and the purified protein solutions. The 
test tubes were incubated at room temperature for 5 minutes before their optical 
density was measured at 595nm using a spectrophotometer (Walker, 2002). The 
dialysate used in the dialysis of the protein in PBS was used as the blank of the 
assay. A calibration curve of optical density at 595nm against the concentration of 
BSA standard solutions was constructed. The calibration curve was then used to 
determine the concentration of the purified protein solution. 
2.7 Bicinchoninic Acid Protein assay 
The BCA assay is a biochemical assay performed to determine the concentration 
of protein in a solution (0.5 μg/mL to 1.5 mg/mL). Similar to the Bradford assay, 
BCA assay is a colorimetric assay where the total protein concentration exhibited 
by a colour change of the sample solution from green to purple in proportion to 
protein concentration. The BCA assay primarily relies on two reactions. Initially, 
peptide bonds in protein reduce Cu2+ ions from the copper (II) sulphate to Cu+. Two 
molecules of bicinchoninic acid then chelate with each Cu+ ion, forming a purple-
coloured product absorbs light at a wavelength of 562 nm. The amount of protein 
present in a solution is quantified by measuring the absorption spectra and 
comparing with protein solutions of known concentration. A calibration curve of 
optical density against the concentration of BSA standard solutions was 
constructed. The calibration curve is used to determine the concentration of the 
purified protein solution. 
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The BCA protein assay was performed for samples that contained DTT by using a 
BCA kit which was compatible with reducing agents as DTT. This kit contained a 
compatible dye known as compatibility reagent, which enables samples containing 
up to 5 mM DTT to be measured. BSA standard solutions of concentrations ranging 
from 0-2.0 mg/mL were prepared and 9 µL of each standard solution was loaded 
into the 96 well plates in duplicates. Similarly, 9 µL of the samples to be tested was 
loaded into the 96 well plates in duplicates. This was followed by the addition of 4μl 
of the compatibility reagent to each of the wells. Finally the prepared BCA reagent 
(50 parts of BCA Reagent A with 1 part of BCA Reagent B) to each well and the 
plate then incubated for 30minutes at 37°C, cooled and read at 590nm using a 
plate reader. Concentrated samples were stored at +4°C before use and remainder 
of the sample was snap frozen using liquid nitrogen and stored at -20°C. 
2.8 Nuclear Magnetic Resonance Spectroscopy  
NMR spectroscopy is one of the most important methods used in the 
pharmaceutical industry as a tool to examine protein drug interactions (Skinner and 
Laurence 2008). For the purpose of this project heteronuclear single quantum 
coherence (HSQC) spectroscopy experiments were performed on the target protein 
S100P in the presence and the absence of ligand, correlating 1H and 15N 
resonances in two-dimensional NMR spectrum. The experiment allows monitoring 
of the binding events in a residue specific manner as it observes the amide groups 
that become chemically unique in the context of the protein's tertiary structure. The 
changes in the protein chemical shift in the presence of a drug indicate binding, 
and the epitope to which the ligand binds of the protein mapped by protein 
resonance assignments. Chemical shift changes are strongly dependent on the 
electronic environment of the nucleus observed. Ligand association with the protein 
moiety will therefore influence the chemical shifts of the nearby protein moieties, 
which measured by NMR by using isotopically labelled protein (Dias and Ciulli 
2014). The chemical shift perturbations of the S100P observed can be mapped to 
protein resonance assignment of S100P which are available on the Biological 
Magnetic resonance Bank (BRMB)(Dias and Ciulli 2014). The protein ligand 
binding sited highlighted by this. Although this is a very effective method in 
determining the protein ligand interactions, the disadvantages of this method is that 
the isotope labelling of the protein is expensive and prohibitive for certain proteins.  
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NMR HSQC titrations were monitored by recording 2D 1H-15N HSQC spectra at 
298.2K on a Burker 600 MHz spectrometer equipped with a cryogenic probes. For 
HSQC characterisation, all protein samples were prepared at a concentration of 0.3 
mM in 20mM MES ((pH 6.5, 10% D2O), 50mM NaCl, 4 mM CaCl2. The ligands 
were added to uniformly 15N-labeled calcium-bound S100P at an excess molar 
ratios of 5:1 and 2:1. The data was collected and processed by Dr. Alain Oregioni 
and Dr.Tom Freinkel from the Francis Crick NMR lab.  
2.9 CCPNMR Analysis 
The data was analysed using a software known as CCPNMR Analysis v.2.4.1. 
(Vranken, Vuister et al. 2015). This spectrum was compared with the standard list of 
chemical shifts obtained from the BRMB library (accession code 17866) and the peaks 
that matched were assigned with their respective residue name and sequence number 
(Markley, Ulrich et al. 2008). This spectrum was then used for as the standard 
spectrum in the ligand titration experiments that followed.  
2.9.1 Defining significant chemical shift perturbations  
In order to determine the active residues the 15N-1H HSQC spectra of  0.3 mM 15N-
labeled S100P and in the complex form with each drug at different concentration ratios 
were overlaid, and any changes chemical shifts of the crosspeaks were observed. 
Chemical shift perturbations (CSP) can be calculated using the following equation.  
:  , 
 where ΔδHN and ΔδN are the chemical shift changes of amide protons and nitrogens, 
respectively and a scaling factor (αN) of 0.15.(Tochio, Hung et al. 2000) 
This is also the same as the ‘shift sum’ value in CCPNMR Analysis. The residues 
that showed a chemical shift perturbations larger than or equal to the average was 
defined as ‘significantly’ perturbed. 
  
- 28 - 
 
2.9.2 Defining active and passive residues 
One of the important parameters in determining the active residues that take part in 
the protein ligand interaction is the relative solvent accessibility (RSA). In order to 
determine this, the accessible surface area (ASA) was calculated for each residue in 
S100P protein using the Helixweb server (http://helixweb.nih.gov/structbio/.)  
The RSA was calculated using equation 2: 
 
  ,  
 
where “Maximum ASA” corresponds to the maximum ASA value, as determined by 
the normalisation scale used, for the focal amino acid (Tien et al. 2013). The 
maximum ASA was obtained from Miller et al. 1987. The Maximum ASA values and 
the RSA values for each residue can be found in the Appendix (1)  
The residues with a relative accessibility of larger than 50% of the main chain were 
selected. The experimental data (chemical shift perturbation) and the solvent 
accessibility were combined and the active residues were defined precisely to use in 
HADDOCK docking software.(De Vries et al. 2010). Passive residues were 
automatically defined by the HADDOCK server, where all solvent accessible surface 
neighbours of the active residues were used.  
2.10  Molecular Docking 
The model of the S100P-ligand complex was generated using the HADDOCK2.0 
web server: (De Vries et al. 2010). The atomic coordinates for calcium-bound 
S100P were obtained from the RCSB Protein Data Bank (PDB), entries 1J55. The 
active residues were defined as residues that exhibited a maximum increase in 
the chemical shift perturbation, as described in section.2.10. The docking trials 
were performed using the standard HADDOCK protocol. Visualisation and 
structural representations were rendered using VMD.v.1.9.2. (Humphrey et al. 
1996). LigPlot+ software was used as a tool for producing schematic 
representations of the Ligand protein binding sites. (Wallace et al. 1995) 
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2.11 Isothermal Titration Calorimetry 
ITC measures heat generated or absorbed upon ligand binding. This is a 
technique for precisely determining binding constants. ITC is also the only 
biophysical technique that take into account the contributions of enthalpy and 
entropy to ligand binding. In this method a biomolecule is placed in the syringe 
and a ligand solution is injected into the cell. The ITC instrument (VP-ITC 
Microcalorimeter) detects the heat generated or absorbed as a result of an 
interaction. This is calculated as the changes in the power required to maintain 
isothermal conditions between the reference and the sample cell. Repeated 
injections of ligand are carried out until the peak sizes become constant. At this 
point the biomolecule is saturated with ligand. On completion of the titration the 
individual peaks are integrated and presented as a Wiseman Plot. This is not a 
suitable method for primary screening, as it requires large amounts of protein and 
is a low throughput technique (Williams and Daviter, 2013).  
For the preparation of protein samples, purified S100P protein was dialysed in 20 
mM MES (pH 6.5), 50 mM NaCl and 2 mM EDTA overnight and then dialysed into 
a fresh buffer of 20 mM MES (pH 6.5), 50 mM NaCl overnight using a dialysis 
membrane with a molecular weight cut-off of approximately 3500 Da. All of the 
protein samples were degassed thoroughly under vacuum for 10 minutes in order 
to remove bubbles prior to the titration experiments ITC was performed using a 
MicroCal VP-ITC calorimeter.  
A 0.015mM solution of CaCl2 solution was placed in the syringe as the ligand and 
titrated into a sample of 0.2 mM S100P protein in the sample cell. All titrations 
were performed at 30°C. A volume of 3 µL was used in the initial injection and 10 
µL per injection for all subsequent titrations. The initial delay of the injection was 
60-s and a delay in the intervals between the injections was120-s.  
The data was analysed using the Origin software by fitting models to calculate: 
reaction stoichiometry (n) binding constant (K), enthalpy (∆H), and entropy (∆S). 
(Williams and Daviter, 2013)  
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3 Results  
3.1 Protein purification analysis by SDS PAGE 
In order to identify the potential candidate compounds that would inhibit the 
interaction of S100P with RAGE, the protein S100P was expressed and purified in 
Escherichia coli using a recombinant plasmid for wild type S100P. The S100P 
protein produced was purified using affinity chromatography by using a HisTrap 
column. At each stage of the purification a sample was obtained for SDS PAGE 
analysis.  
Figure 5 shows the SDS PAGE analysis of one of the purifications performed. All 
the SDS PAGE gel profiles for the purifications were similar. The majority of the 
S100P protein was detected in the sample obtained during the preparation of the 
bacterial cell lysate (Lane 2) indicated by the intense band in Lane 2 (~12KDa). 
This band was faint in Lane 3 which indicates that the protein S100P was depleted 
in the filtered lysate flow-through, as the protein was bound to the HisTrap column 
at this stage. However there were other protein bands detected in the filtered lysate 
flow-through. The Wash 1 (Lane 4) and Wash 2 (Lane 5) flow-through samples did 
not produce any bands. 
The EB 1 had a higher concentration of imidazole than the wash buffer. However in 
the SDS PAGE analysis of the EB 1 fractions the protein bands were faint. The 
abundance of the protein S100P was detected in the EB 2 flow-through, indicated 
by the intense band at ~12kDa on Lane 8.  
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Figure 5: Protein purification analysis by SDS PAGE. (A) Lane 2 indicates the filtered lysate 
sample lane, and lane 3 indicates the flow through of the filtered lysate. The S100P protein 
band (~12KDa) was absent in this lane. Lanes 4 and 5 were the wash buffer 1 and wash buffer 
2 respectively. Lane 6 had had the S100P sample dialysed in buffer( EB 1 fractions containing 
most amount of protein pooled together and dialysed in appropriate buffer) (B)  The lanes 2, 3, 
4,5 ,6 and 7 had the EB 1 fractions 1 to 6 respectively. Lane had the EB 2.  The molecular 
weight markers of gel A and Gel B were loaded at Lane 8 and 9 respectively. Sample buffer 
was added to the empty lanes.   
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3.2 Protein Concentration Assay  
The protein concentration was initially determined by performing the Bradford assay. 
However this method used 200 µL of sample, therefore the BCA assay with 
compatibility for reducing agents was performed in subsequent purifications. A sample 
volume of only 9 µL was required for the BCA assay.  
Both NMR and ITC were done in two sessions, and therefore fresh protein was purified 
for each session for each technique. The protein concentration of the S100P samples 
used on the first session of NMR data collection was calculated to be 295µM and 
second session calculated to be 430µM. The protein concentration of the S100P 
samples used on the first session of ITC was calculated to be 301.8 µM and second 
session was calculated to be 356 µM 
 
3.3 NMR Spectroscopy for the characterisation of the binding interface 
between S100P and the ligands 
NMR is an invaluable tool for the drug discovery, particularly in the characterisation 
and optimisation of lead compounds. In this project NMR was used for examining the 
protein–ligand interactions emphasising identification of the sites to which the drug 
compounds bind on the protein. The binding interface was mapped as a perturbation 
of the chemical shifts of the cross peaks in 15N-1H HSQC spectra of  S100P protein in 
the ligand-protein complex. A series of 15N-1H HSQC titrations was performed where 
the ligand (cromolyn, C72, IBS409, IBS798, and IBS863) was added in excess to 
S100P, at a ratio of 2:1 and increased further to 5:1 excess of ligand to protein 
respectively. Changes in the 15N-1H backbone resonance of S100P were detected on 
addition of the ligand, and these were analysed relative to the spectra of  S100P. 
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3.3.1 NMR characterisation of the binding interface between cromolyn and 
S100P 
The initial titration performed was with cromolyn as the ligand molecule at ligand to 
protein concentrations ratios 2:1 and 5:1 respectively. The chemical shift perturbations 
for the peaks at each concentration of cromolyn were obtained using CCPNMR 
Analysis shift sum value. The average CSP for each titration was used as a cut off 
point for determining the significantly shifted residues.  
Figure 6 (A) demonstrated the overlaid spectral images of 0.28 mM 15N-labeled S100P 
(black) and in the complex form with 0.55 mM of the cromolyn (green). Figure 6 (B) 
shows a bar graph demonstrating the chemical shift perturbations of each residue, 
where the significantly perturbed residues were determined as residues with CSP 
greater than or equal to an average CSP of 0.004. The solvent accessibility for the 
residues were calculated using equation 2 and the most perturbed residues that were 
accessible to the solvent were determined to be 3Glu, 10Met, 4Leu, 16Ser, 17Arg, 
26Gln, 43Gly, 86His, 89Phe, 90Glu, 91Lys, 92Ala, 93Gly as labelled in Figure 6 (A) 
Figures 7 (A) demonstrated the overlaid spectral images of 0.28 mM 15N-labeled 
S100P (black) and in the complex form with 1.35 mM of the cromolyn (green). Figure 7 
(B) shows a bar graph demonstrating the chemical shift perturbations of each residue, 
where the significantly perturbed residues were determined as residues with CSP 
greater than or equal to an average CSP of 0.009. The solvent accessibility for the 
residues were calculated using equation 2 and the most perturbed residues that were 
accessible to the solvent were determined to be 3Glu, 4Leu, 10Met, 17Arg, 23Gly, 
43Gly, 56Lys’ 86His’ 89Phe’ 90Glu, 91Lys, 92Ala, 93Gly, 94Leu as labelled in Figure 7 
(A) 
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Figure 6: (A) Overlay of the 15N-1H HSQC spectra of 0.28 mM 15N-labeled S100P (black) and in 
the complex form with 0.55 mM of the cromolyn (green), are shown. (B) Bar graph of the 
weighted average of the chemical shift (1H and 15N) variations of the amino acid residues in the 
S100P–cromolyn adduct at concentration ratio 2:1, cromolyn to S100P respectively. The black 
dashed line represents the average chemical shift perturbation (Δppm ≥ 0.004 ppm).  
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Figure 7: (A) Overlay of the 15N-1H HSQC spectra of 0.28 mM 15N-labeled S100P (black) and in 
the complex form with 1.35 mM of the cromolyn (green), are shown. (B) Bar graph of the 
weighted average of the chemical shift (1H and 15N) variations of the amino acid residues in the 
S100P–cromolyn adduct at concentration ratio 5:1, cromolyn to S100P respectively. The black 
dashed line represents the average chemical shift perturbation (Δppm ≥ 0.009 ppm).  
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3.3.2 Modelling of the S100P-cromolyn complex when the concentration of 
cromolyn to S100P was 2:1  
The molecular docking web server HADDOCK was used with the NMR-derived 
restraints to model the S100P–cromolyn complex. There were 200 structures of 
solvent refinement from HADOCK that were separated into 2 clusters when the 
cromolyn to S100P was at a concentration ratio 2:1. When the lowest energy 
conformations of the clusters were analysed it showed that the cromolyn moiety was 
situated in the hydrophobic pocket of S100P. The residues that involved in the 
interaction are shown in the LigPlot analysis in Figure 8. There were hydrophobic 
interactions within cromolyn and the S100P at residues 5Glu, 8Met, 9Gly, 12Ile, 26Glu, 
86His, 89Phe and 90Glu. There were some hydrogen bonds that were observed 
between the residues formed between the hydroxyl group of cromolyn and 6Thr, 9Met, 
91Lys, 92Alaand 93Gly. The interaction between the cromolyn and S100P (at a 
concentration ratio of 2:1 respectively) dominated by hydrophobic interactions. 
   
Figure 8 A schematic representation of the residues that involved in the interaction within 
cromolyn and the S100P at a concentration ratio 2:1 
. 
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Residues that involved in the interaction was mapped on S100P dimer. It was 
observed that the residues that are involved in the interaction were located mainly in 
the Helix-1 and Helix- 4 as demonstrated in Figure 9 (A).This was a hydrophobic 
pocket of the S100P protein (Figure 9 (B)). 
  
Figure 9 HADDOCK structure of the S100P−cromolyn complex with 2:1 cromolyn.  
(A) Ribbon-stick representation of the overlap of the S100P−cromolyn complex structure. 
Cromolyn is shown in yellow of the S100P homodimer and the domains 1 and 2 of the S100P 
dimer are coloured in red and blue respectively. The residues that are involved in hydrogen 
bonding are shown in blue-green colour and the residues taking part in hydrophobic 
interactions are in purple. (B) Representation of the S100P−cromolyn complex coloured by 
charged residue type. Cromolyn was displayed in yellow. The positively charged, negatively 
charged, nonpolar and polar residue surfaces are represented in blue, red and white, and lime 
green respectively.  
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3.3.1 Modelling of the S100P-cromolyn complex when the concentration of 
cromolyn to S100P was 5:1. 
The molecular docking web server HADDOCK was used with the NMR-derived 
restraints to model the S100P–cromolyn complex. There were 199 structures of 
solvent refinement from HADOCK that were separated into 2 clusters when the 
cromolyn to S100P was at a concentration ratio 5:1. The lowest energy conformations 
of the clusters were further analysed, and it demonstrated that the cromolyn molecule 
moiety was situated at the hydrophobic pocket of the S100P. The residues that are 
involved in the interaction are shown in the LigPlot analysis in Figure 10. There were 
hydrophobic interactions within cromolyn and the S100P; at a concentration ratio 5:1 
respectively, were 1Met, 5Glu, 8Met, 9Gly, 88Try, 90Glu, 89Phe, 91Lys and 93Gly. 
Hydrogen bonds between were formed between 6Thr, 26Gln and 94Leu and the 
hydroxyl group of cromolyn, except for one hydrogen bond with 26Gln, where the 
hydrogen bond was with the oxygen in the phenyl ring. The number of interactions 
between the cromolyn and S100P (at a concentration ratio of 5:1 respectively) is 
dominated by hydrophobic interactions. 
 
Figure 10 A schematic representation of the residues that are involved in the interaction within 
cromolyn and the S100P at a concentration ratio 5:1 respectively. The atoms shown in lime 
green are hydrogen atoms of the NH2 group of 26Gln. 
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Residues that are involved in the interaction was mapped on S100P dimer. It was 
observed that the residues that are involved in the interaction were located mainly in 
the Helix-1 and Helix-4 as demonstrated in 
 
 
Figure 11(A).This was a hydrophobic pocket of the S100P protein (
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Figure 11(B)). 
 
 
 
Figure 11 HADDOCK structure of the S100P−cromolyn complex with 5:1 cromolyn. 
 (A) Ribbon-stick representation of the overlap of the S100P−cromolyn complex structure. 
Cromolyn is shown in yellow of the S100P homodimer and the domains 1 and 2 of the S100P 
dimer are coloured in red and blue respectively. The residues that are involved in hydrogen 
bonding are shown in blue-green colour and the residues taking part in hydrophobic 
interactions are in purple. (B Representation of the S100P−cromolyn complex coloured by 
charged residue type. Cromolyn was displayed in yellow. The positively charged, negatively 
charged, nonpolar and polar residue surfaces are represented in blue, red and white, and lime 
green respectively. 
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3.3.1 NMR characterisation of the binding interface between C72 and S100P 
The next titration was the drug C72 at concentrations ratios 2:1 and 5:1 with the  15N 
labelled S100P. The combined chemical shift perturbations for the peaks at each 
concentration of C72 were calculated using in analysis as the shift sum.  
Figures 12 (A) shows the overlaid spectra of 0.28 mM 15N-labeled S100P (black) and 
in the complex form with 0.55 mM of the C72 (cyan). Figure 12 (B) shows a bar graph 
demonstrating the chemical shift perturbations of each residue, where the significantly 
perturbed residues were determined as residues with CSP greater than or equal to an 
average CSP of 0.03. The solvent accessibility for the residues were calculated using 
equation 2 and the most perturbed residues that were accessible to the solvent were 
determined to be 4Leu, 10Met, 17Arg, 20Gly, 26Gln, 43Gly, 60Asp, 72Ser, 76Val, 
79Ala, 86His, 90Glu, 91Lys, 92Ala, 93Gly, 94Leu as labelled in Figure 10 (A). 
As the concentration of C72 was titrated until a ligand to protein concentration was 5:1, 
the spectrum produced was very unclear, and it was impossible to assign any peaks 
for this spectrum. 
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Figure 12(A) Overlay of the 15N-1H HSQC spectra of 0.28 mM 15N-labeled S100P (black) and in 
the complex form with 0.55 mM of the C72 (cyan), are shown. (B) Bar graph of the weighted 
average of the chemical shift (1H and 15N) variations of the amino acid residues in the S100P–
C72 adduct at concentration ratio 2:1, C72 to S100P respectively. The range of shifts is double 
that of cromolyn.  The black dashed line represents the average chemical shift perturbation 
(Δppm ≥ 0.03 ppm). 
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3.3.2 Modelling of the S100P–C72 complex 
Similar to cromolyn the modelling of the S100P-C72 complex was by using the 
molecular docking web server HADDOCK. The active residues were defined as 
significantly perturbed residues there was considerable shifts differences observed in 
the 15N-1H HSQC backbone upon S100P-C72 complex formation. In total, 200 
structures of solvent refinement from HADDOCK resulted in a single cluster for the 
initial titration of C72 to S100P concentration ratio 2:1. The lowest energy 
conformations of the cluster were further analysed, and it demonstrated that the C72 
molecule moiety was also situated at the hydrophobic pocket of the S100P. 
Ligplot+ software did not create a schematic representation of the C72-S100P binding 
sites due to complexity of the arrangement. Therefore the interactions were assessed 
based on the residues that are at close proximity to the ligand. The Figure 13 below 
shows the surface view of the residues that are involved in the interaction. The 44Phe, 
92Ala, 93Gly contain hydrophobic regions that are at close proximity to the drug, 
indicating that the hydrophobic bonds in this region.  
 
Figure 13 The surface view of the residues that are involved in the C72-S100P interaction. 
The ligand C72 is coloured light blue, and the positively charged, negatively charges polar and 
non- polar residues are shown in blue, red, lime green and white respectively. 
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Residues that are involved in the interaction was mapped on S100P dimer. It was 
observed that the residues that are involved in the interaction were located in the 
Helix-4 as demonstrated in Figure 14 
 
 
Figure 11(A).This was a hydrophobic pocket of the S100P protein (Figure 14 (B)). 
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Figure 14 HADDOCK structure of the S100P−C72 complex with 5:1 C72. (A) Ribbon-stick 
representation of the overlap of the S100P−C72 complex structure. C72 is shown in yellow of 
the S100P homodimer and the domains 1 and 2 of the S100P dimer are coloured in red and 
blue respectively. The residues that are involved in hydrogen bonding are shown in blue-green 
colour and the residues taking part in hydrophobic interactions are in purple. (B) Representation 
of the S100P−C72 complex coloured by charged residue type. C72 was displayed in yellow. 
The positively charged, negatively charged, nonpolar and polar residue surfaces are 
represented in blue, red and white, and lime green respectively 
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3.3.1 NMR characterisation of the binding interface between IBS409 and 
S100P 
The next titration were performed on the drug compound IBS409 at concentrations 
ratios 2:1 and 5:1 with the  15N labelled S100P. The combined chemical shift 
perturbations for the peaks at each concentration of IBS409 were calculated using in 
analysis as the shift sum. The figures are included in the appendix 2. 
Figure 28 (A) shows the overlaid spectra of 0.42 mM 15N-labeled S100P (black) and in 
the complex form with 0.84 mM IBS409 (magenta). Figure 28 (B) shows a bar graph 
demonstrating the chemical shift perturbations of each residue, where the significantly 
perturbed residues were determined as residues with CSP greater than or equal to an 
average CSP of 0.020. The solvent accessibility for the residues were calculated using 
equation 2 and the most perturbed residues that 3Glu, 4Leu, 10Met, 17Arg, 52Asp, 
56Lys, 59Lys. 63Ala, 76Val, 79Ala, 86His. 90Glu, 92Ala were accessible to the solvent 
were determined to be as labelled in Figure 28 (A) 
Figures 29 (A) shows the overlaid spectra of 0.42 mM 15N-labeled S100P (black) and 
in the complex form with 2.02 mM IBS409 (magenta). Figure 29 (B) shows a bar graph 
demonstrating the chemical shift perturbations of each residue, where the significantly 
perturbed residues were determined as residues with CSP greater than or equal to an 
average CSP of 0.029. The solvent accessibility for the residues were calculated using 
equation 2 and the most perturbed residues that were accessible to the solvent were 
determined to be 3Glu, 4Leu, 10Met, 17Arg, 26Gln, 38Glu, 76Val, 79Ala, 86His, 
91Lys, 92Ala, 93Gly as labelled in Figure 29 (A) 
 
.  
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3.3.2 Modelling of the S100P-IBS409 complex when the concentration of 
IBS409 to S100P was 2:1  
HADDOCK clustered 200 structures in 1 cluster, which represents 100.0 % of the 
water-refined models for the titration of IBS409 to S100P at a concentration ratio 2:1. 
The schematic representation in Figure 15 shows the residues that are involved in the 
interaction. There were hydrophobic interactions between the S100P residues 57Leu, 
60Asp, 61Leu, 76Val, 77Phe, 79Ala, 80Ala and the ligand IBS409 at a concentration 
ratio 2:1. Hydrogen were formed between 83Se, 84Ala and 87Lys and the hydroxyl 
group of IBS409, The number of interaction between the IBS409 and S100P (at a 
concentration ratio of 2:1 respectively is dominated by hydrophobic interactions. 
   
Figure 15 A schematic representation of the residues that are involved in the interaction within 
IBS409 and the S100P at a concentration ratio 2:1.  
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Residues that are involved in the interaction was mapped on S100P dimer. It was 
observed that the residues that are involved in the interaction were located in the 
Helix- 3, and Helix-4 as demonstrated in Figure 15(A).This was a hydrophobic pocket 
of the S100P protein (Figure 15 (B)). 
 
Figure 16 HADDOCK structure of the S100P- IBS409 complex with 2:1 IBS409 
. (A) Ribbon-stick representation of the overlap of the S100P−IBS409 complex structure. 
IBS409 is shown in yellow of the S100P homodimer and the domains 1 and 2 of the S100P 
dimer are coloured in red and blue respectively. The residues that are involved in hydrogen 
bonding are shown in blue-green colour and the residues taking part in hydrophobic 
interactions are in purple. (B) Representation of the S100P−IBS409 complex coloured by 
charged residue type. IBS409 was displayed in yellow. The positively charged, negatively 
charged, nonpolar and polar residue surfaces are represented in blue, red and white, and lime 
green respectively 
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3.3.3 Modelling of the S100P-IBS409 complex when the concentration of 
IBS409 to S100P was 5:1  
HADDOCK clustered 200 structures in 1 cluster, which represents 100.0 % of the 
water-refined models for the complex of IBS409 to S100P at a concentration ratio 
5:1. The schematic representation in Figure 15 shows the residues that are involved 
in the interaction. There were hydrophobic interactions between the S100P residues 
9Phe, 79Ala, 80Ala, 83Ser, 84Ala, 87Lys, 88Tyr and 92 Ala and the ligand IBS409 at 
a concentration ratio 5:1. Hydrogen were formed between 90Glu, 91Gly, 93Gly and 
the hydroxyl group of IBS409, The interaction between the IBS409 and S100P (at a 
concentration ratio of 5:1 respectively) is dominated by hydrophobic interactions.  
  
Figure 17 A schematic representation of the residues that are involved in the interaction within 
IBS409 and the S100P at a concentration ratio 5:1.  
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Residues that are involved in the interaction was mapped on S100P dimer in VMD. It 
was observed that the residues that are involved in the interaction were located in the 
Helix-1 and Helix-4 as demonstrated in Figure 18(A).This was a hydrophobic pocket 
of the S100P protein (Figure 18 (B)). 
 
Figure 18 HADDOCK structure of the S100P- IBS409 complex with 5:1 IBS409 
. (A) Ribbon-stick representation of the overlap of the S100P−IBS409 complex structure. 
IBS409 is shown in yellow of the S100P homodimer and the domains 1 and 2 of the S100P 
dimer are coloured in red and blue respectively. The residues that are involved in hydrogen 
bonding are shown in blue-green colour and the residues taking part in hydrophobic 
interactions are in purple. (B) Representation of the S100P−IBS409 complex coloured by 
charged residue type. IBS409 was displayed in yellow. The positively charged, negatively 
charged, nonpolar and polar residue surfaces are represented in blue, red and white, and lime 
green respectively 
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3.3.4 NMR characterisation of the binding interface between IBS798 and 
S100P 
The next titration were performed on the drug compound IBS798 at concentrations 
ratios 2:1 and 5:1 with the  15N labelled S100P. The combined chemical shift 
perturbations for the peaks at each concentration of IBS798 were calculated using in 
analysis as the shift sum. The figures are included in the appendix 3. 
Figure 30 (A) shows the overlaid spectra of 0.42 mM 15N-labeled S100P (black) and in 
the complex form with 0.84 mM of the IBS798 (orange). Figure 30 (B) shows a bar 
graph demonstrating the chemical shift perturbations of each residue, where the 
significantly perturbed residues were determined as residues with CSP greater than or 
equal to an average CSP of 0.018. The solvent accessibility for the residues were 
calculated using equation 2 and the most perturbed residues that were accessible to 
the solvent were determined to be  3Glu, 4Leu, 8Met, 17Arg, 38Glu, 39Lys, 52Asp, 
59Lys, 63Ala, 76Val, 90Glu, 92Ala as labelled in Figure 30 (A) 
Figures 31 (A) shows the overlaid spectra of 0.42 mM 15N-labeled S100P (black) and 
in the complex form with 2.02 mM of the IBS798 (orange). Figure 31 (B) shows a bar 
graph demonstrating the chemical shift perturbations of each residue, where the 
significantly perturbed residues were determined as residues with CSP greater than or 
equal to an average CSP of 0.018. The solvent accessibility for the residues were 
calculated using equation 2 and the most perturbed residues that were accessible to 
the solvent were determined to be as 3Glu, 4Leu, 17Arg, 65Gly, 76Val, 79Ala, 84Ala, 
90Glu, 92Ala, 93Gly, 94Leu labelled in Figure 31 (A) 
. 
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3.3.5 Modelling of the S100P-IBS798 complex when the concentration of 
IBS798 to S100P was 2:1  
HADDOCK clustered 200 structures in 1 cluster, which represents 100.0 % of the 
water-refined models for the complex of IBS798 to S100P at a concentration ratio 
2:1. The schematic representation in Figure 19 shows the residues that are 
involved in the interaction. There were hydrophobic interactions between the 
S100P residues 44Phe, 57Leu, 60Asp, 61Leu, 63Ala, 76Val, 77Phe, 81Ile, and 
the ligand IBS798 at a concentration ratio 2:1. The interaction between the IBS798 
and S100P (at a concentration ratio of 2:1 respectively) is dominated by 
hydrophobic interactions.  
 
 
Figure 19 A schematic representation of the residues that are involved in the interaction within 
IBS798 and the S100P at a concentration ratio 2:1.  
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Residues that are involved in the interaction was mapped on S100P dimer. It was 
observed that the residues that are involved in the interaction were located mainly in the 
Helix-4 and the linker regions as demonstrated in Figure 20 (A).This was a hydrophobic 
pocket of the S100P protein (Figure 20(B)). 
 
 
Figure 20 HADDOCK structure of the S100P- IBS798 complex with 2:1 IBS798 
. (A) Ribbon-stick representation of the overlap of the S100P−IBS798 complex structure. 
IBS798 is shown in yellow of the S100P homodimer and the domains 1 and 2 of the S100P 
dimer are coloured in red and blue respectively. The residues that are involved in hydrogen 
bonding are shown in blue-green colour and the residues taking part in hydrophobic 
interactions are in purple. (B) Representation of the S100P−IBS798 complex coloured by 
charged residue type. IBS798 was displayed in yellow. The positively charged, negatively 
charged, nonpolar and polar residue surfaces are represented in blue, red and white, and lime 
green respectively 
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3.3.6 Modelling of the S100P-cromolyn complex when the concentration of 
IBS798 to S100P was 5:1  
HADDOCK clustered 200 structures in 1 cluster, which represents 100.0 % of the 
water-refined models for the complex of IBS798 to S100P at a concentration ratio 
5:1. The schematic representation in Figure 21 shows the residues that are 
involved in the interaction. There were hydrophobic interactions between the 
S100P residues 8Met, 44Phe, 84Ala, 85Cys, 88Tyr, 89Phe, 91Lys, 92 Ala, and 
the ligand IBS798 at a concentration ratio 5:1  Hydrogen were formed between 
87Lys, 90Glu and 93Gly and the hydroxyl group of IBS798, The interaction 
between the IBS798 and S100P (at a concentration ratio of 5:1 respectively) is 
dominated by hydrophobic interactions. 
 
Figure 21 A schematic representation of the residues that are involved in the interaction within 
IBS798 and the S100P at a concentration ratio 2:1.  
 
- 55 - 
 
Residues that are involved in the interaction was mapped on S100P dimer. It was 
observed that the residues that are involved in the interaction were located mainly in 
the Helix-1 and Helix 4 and also in the linker region as demonstrated in Figure 22(A). 
This was partly in the hydrophobic pocket, of the S100P protein, and partly exposed 
to the polar and basic residues in the structure as demonstrated in Figure 22(B). 
 
Figure 22 HADDOCK structure of the S100P−IBS798 complex with 5:1IBS798. 
(A) Ribbon-stick representation of the overlap of the S100P−IBS798 complex structure. IBS798 
is shown in yellow of the S100P homodimer and the domains 1 and 2 of the S100P dimer are 
coloured in red and blue respectively. The residues that are involved in hydrogen bonding are 
shown in blue-green colour and the residues taking part in hydrophobic interactions are in 
purple. (B) Representation of the S100P−IBS798 complex coloured by charged residue type. 
IBS798 was displayed in yellow. The positively charged, negatively charged, nonpolar and 
polar residue surfaces are represented in blue, red and white, and lime green respectively 
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3.3.7 NMR characterisation of the binding interface between IBS863 and 
S100P 
The next titration were performed on the drug compound IBS863 at concentrations 
ratios 2:1 and 5:1 with the  15N labelled S100P. The combined chemical shift 
perturbations for the peaks at each concentration of IBS863 were calculated using in 
analysis as the shift sum. The figures are included in the appendix 4. 
Figure 32 (A) shows the overlaid spectra of 0.42 mM 15N-labeled S100P (black) and in 
the complex form with 0.84 mM of the (red). Figure 32 (B) shows a bar graph 
demonstrating the chemical shift perturbations of each residue, where the significantly 
perturbed residues were determined as residues with CSP greater than or equal to an 
average CSP of 0.008. The solvent accessibility for the residues were calculated using 
equation 2 and the most perturbed residues that were accessible to the solvent were 
determined to be 3Glu, 4Leu, 10Met, 12Ile, 17Arg, 39Lys, 43Gly, 63Ala, 76Val, 86His, 
92Ala as labelled in Figure 32 (A) 
Figure 33 (A) shows the overlaid spectra of 0.42 mM 15N-labeled S100P (black) and 
in the complex form with 2.02 mM of the IBS863 (red). Figure 33 (B) shows a bar 
graph demonstrating the chemical shift perturbations of each residue, where the 
significantly perturbed residues were determined as residues with CSP greater than or 
equal to an average CSP of 0.08. The solvent accessibility for the residues were 
calculated using equation 2 and the most perturbed residues that were accessible to 
the solvent were determined to be as 3Glu, 10Met, 17Arg, 26Gln, 38Glu, 39Lys, 
56Lys, 60Asp, 63Ala, 65Gly, 76Val, 84Ala, 86His, 89Phe, 92Ala, 94Leu as labelled in 
Figure 33 (A) 
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3.3.8 Modelling of the S100P-IBS863 complex when the concentration of 
IBS863 to S100P was 2:1 
HADDOCK clustered 200 structures in 1 cluster, which represents 100.0 % of the 
water-refined models for the complex of IBS863 to S100P concentration ratio 2:1. 
The schematic representation in Figure 23 shows the residues that are involved in 
the interaction. There were hydrophobic interactions between the S100P residues 
4Leu, 7Ala, 8Met, 9Gly, 11Ile, 81Ile and 85Cys. and the ligand IBS863 at a 
concentration ratio 2:1 Hydrogen bonds were formed between residues 7Ala, 10Met, 
12Ile and the hydroxyl group of IBS863, The interaction between the IBS863 and 
S100P (at a concentration ratio of 2:1 respectively is dominated by hydrophobic 
interactions. 
  
Figure 23 A schematic representation of the residues that are involved in the interaction within 
IBS863 and the S100P at a concentration ratio 2:1.  
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Residues that are involved in the interaction was mapped on S100P dimer. It was 
observed that the residues that are involved in the interaction were located in the 
Helix-1 Helix-4 as demonstrated in Figure 24 (A). This was in the hydrophobic 
pocket, of the S100P protein as demonstrated in Figure 24(B). 
 
Figure 24 HADDOCK structure of the S100P−IBS863 complex with IBS863  
(A) Ribbon-stick representation of the overlap of the S100P−IBS863 complex structure. IBS863 
is shown in yellow of the S100P homodimer and the domains 1 and 2 of the S100P dimer are 
coloured in red and blue respectively. The residues that are involved in hydrogen bonding are 
shown in blue-green colour and the residues taking part in hydrophobic interactions are in 
purple. (B) Representation of the S100P−IBS863 complex coloured by charged residue type. 
IBS863 was displayed in yellow. The positively charged, negatively charged, nonpolar and 
polar residue surfaces are represented in blue, red and white, and lime green respectively 
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3.3.9 Modelling of the S100P-IBS863 complex when the concentration of 
IBS863 to S100P was 5:1  
 HADDOCK clustered 200 structures in 1 cluster, which represents 100.0 % of the 
water-refined models for the titration of IBS863 to S100P concentration ratio 5:1. The 
schematic representation in Figure 25 shows the residues that are involved in the 
interaction. There were hydrophobic interactions between the S100P residues 4Leu, 
7Ala, 8Met, 9Gly, 11Ile, 85Cys and 81Ile and the ligand IBS863 at a concentration 
ratio 2:1. Hydrogen bond was present between the SH group of 85Cys and the NH. 
The hydrogen bonding occurred between the cyclic nitrogen group of the drug and a 
hydroxyl group of 87Lys, and amine groups in 89Phe and 91Lys. The interaction 
between the IBS863 and S100P (at a concentration ratio of 5:1 respectively is 
dominated by hydrophobic interactions. 
  
Figure 25 A schematic representation of the residues that are involved in the interaction within 
IB863 and the S100P at a concentration ratio 5:1.  
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Residues that are involved in the interaction was mapped on S100P dimer. It was 
observed that the residues that are involved in the interaction were located in mainly 
the Helix-1 and 4 as demonstrated in Figure 26 (A). This was in the hydrophobic 
pocket of the S100P protein structure as demonstrated in Figure 26 (B).  
 
Figure 26 HADDOCK structure of the S100P−IBS863 complex with IBS863  
(A) Ribbon-stick representation of the overlap of the S100P−IBS863 complex structure. IBS863 
is shown in yellow of the S100P homodimer and the domains 1 and 2 of the S100P dimer are 
coloured in red and blue respectively. The residues that are involved in hydrogen bonding are 
shown in blue-green colour and the residues taking part in hydrophobic interactions are in 
purple. (B) Representation of the S100P−IBS863 complex coloured by charged residue type.  
IBS863 was displayed in yellow. The positively charged, negatively charged, nonpolar and 
polar residue surfaces are represented in blue, red and white, and lime green respectively 
 
3.4 Isothermal titration Calorimetry 
The ITC assay was performed in order to assess the binding affinity and the 
stoichiometry of the S100P-ligand complexes, by determining the heat changes during 
the interaction. The initial assay was performed with the ligand cromolyn and C72. 
[The Wilmans plot for these experiments are in Appendix 5, Figure 34 (B) and Figure 
35 (B).]  However from these experiments very little or no binding was observed, and 
therefore binding parameters could not be determined. ITC was performed by using 
CaCl2 as a ligand as a positive control for the assay. This titration was successful 
giving a stoichiometry of binding interaction is 1:4. The binding isotherm for the 
interaction between S100P and the CaCl2 is presented in Figure 27.  
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Figure 27 The ITC titration of calcium chloride to S100P. (A) Raw data of the ITC titration 
with CaCl2. (B) The Wilmans plot of CaCl2 titration, where data was fitted a non-linear least 
square approach to the ‘one set of sets’ site model. This yielded a dissociation constant 
of Kd = 6.62E5±0.52E5 µM with additional parameters of N = 4±0, ΔH = -3988± 156.2 kcal/mol, 
and ΔS = 13.6 cal/mol/deg. The stoichiometry of binding interaction is 1:4.  
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4 Discussion   
Earlier studies have associated the aggressiveness of PDAC to the dysregulated 
expression of the calcium binding protein S100P. S100P is secreted from cancer 
cells and acts via interaction with the RAGE receptor. The activation of the RAGE 
receptor through the binding of S100P leads to the key signalling events as 
activation of the MAP kinase and NF-κB.(Arumugam et al. 2004). Blocking S100P 
function has been shown to reduce tumour growth and metastasis (Arumugam et 
al. 2004). This data suggests that S100P is a promising therapeutic target. An 
effective strategy in the treatment of diseases caused by the overexpression of 
the S100P could be to prevent the formation of this S100P-RAGE complex. Dr. 
Sharon Rossiter and her team have developed some new chemotherapy drug 
compounds that are specifically aimed at attaching to and inhibiting RAGE from 
binding to S100P.  In the present study the interactions between the drug 
compounds and the S100P protein were investigated, using biophysical 
techniques including NMR and ITC. In order to perform these assays, the 
recombinant plasmid bearing the wildtype human S100P protein in was 
expressed in E. coli Star bacterial cells. The S100P protein expressed was 
purified by affinity chromatography using a HisTrap column and the purity of the 
protein was assessed using SDS PAGE.  
4.1 Analysis of the purity of the protein purified by SDS PAGE 
SDS PAGE is the most common polyacrylamide gel electrophoresis method used 
for assessing the purity of a protein sample. In SDS PAGE the SDS shields the 
respective charge of the proteins in a mixture giving them a negative charge and 
DTT is a reducing agent that cleaves di-sulphide bonds and converts protein to 
their secondary structure. This allows the proteins to be separated based on their 
molecular weight. The target protein band can be identified using the apparent 
molecular weight obtained by including standard molecular weight markers in the 
analysis (Walker, 2002). 
There were several purifications performed during this project and an SDS PAGE 
assay was performed for the samples collected at each stage, for each of the 
purifications. In all of these purification gels bands of a similar profile were 
observed. The most abundant protein detected in the bacterial lysate sample was 
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at a molecular weight of ~12KDa, Post application of filtered lysate sample to the 
column the intensity of the band at ~12kDa faded, this implies that the protein 
bound to the HisTrap column at this stage. The S100P protein prepared includes 
of a hexa-histidine-tag, therefore it has a high selective affinity for Ni2+ ions in the 
Nickel Sepharose column. Other host cell protein bands were detected in the 
filtered lysate flow-through, this indicates that the histidine-tagged S100P binding 
to the column is highly selective (Gelifesciences, 2015). The filtered lysate sample 
has a low concentration (25 mM) of imidazole. Imidazole competes with the 
proteins to bind to the Nickel Sepharose column. The low concentration of 
imidazole in the filtered lysate sample prevents unwanted host cell proteins from 
binding to the column. 
The Wash 1 and Wash 2 flow-through sample lanes usually had no bands or very 
faint bands. The initial wash step with the lysis buffer was performed in order to 
facilitate the filtered lysate sample passing through the column. The second step 
was with a buffer that had a slightly higher concentration (100 mM) of imidazole 
than the lysis buffer which ensures the removal of contaminants that may 
otherwise be co-purified with the histidine-tagged S100P. At higher 
concentrations, imidazole decreases the binding of the histidine-tagged protein to 
the Ni Sepharose column (Gelifesciences, 2015). 
The EB 1 fraction lanes usually contained a protein band at ~12kDa. The EB 1 
contained a higher concentration of imidazole (350mM) than the wash buffer, 
causing the elution of histidine-tagged S100P protein. However, most of the 
protein S100P was detected in the EB 2 fractions, indicated by an intense band at 
~12kDa. The intensity of the S100P protein band indicated that the most 
abundant protein present in the sample was S100P and the purification was 
successful. However the level of purity of the protein sample could be obtained 
through an additional purification step by gel filtration.   
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4.2 NMR characterisation of the binding interface between the ligands 
and S100P 
Two-dimensional NMR 1H-15N HSQC experiment is a useful method for the 
identification of ligand binding sites on proteins. The spectra provide information 
on the connections between the amide protons (NH) and the nitrogen atoms 
connected. The peaks in these spectra correspond to the NH group of each 
residue, and act as a ‘fingerprint’ for the protein.   
In order to obtain a greater understanding of the interaction between the S100P 
protein and the drug compounds, a series of 2-D HSQC NMR experiments 
performed. The initial experiment was performed with 0.3mM S100P protein in 
20mM MES (pH 6.5), 50mM NaCl, 4 mM CaCl2 and 10% D2O. This initial 
spectrum overlaid with calcium bound S100P spectrum previously deposited in 
the BRMB (accession code 17866) and their peaks were compared. Most of the 
peaks in the BRMB spectrum (reference) matched with the peaks of the spectrum 
of expressed and purified for this studies. This confirmed that the purified protein 
was S100P with minimal impurities. This spectrum was used as the reference 
spectrum for the rest of the assessments with that preparation of S100P. A Bruker 
600Hz spectrometer equipped with cryogenic probes were used for the purpose 
of these experiments.  
Previous studies have demonstrated that in mouse models, cromolyn has the ability 
to block S100P interaction with its receptor RAGE in and thereby reduce growth and 
invasion of pancreatic cancer. (Arumugam et al. 2006) Another study also 
demonstrated binding affinity using NMR as an analysis tool. (Penumutchu et al. 
2014b). Since cromolyn has been studied in relation to being an S100P inhibitor, in 
this study cromolyn was used as a positive control. The next set of experiments 
included the S100P protein in the presence of excess anti-allergy drug cromolyn at 
ratios of 2:1 and 5:1. The experiment of ligand addition was performed as titration 
NMR by increasing the ligand ratio to the S100P. Upon the addition of the ligand 
(cromolyn) there were changes in the 15N-1H that were observed in the spectra. The 
15N-1H backbone resonance of the S100P relative to that of the  protein spectra 
demonstrated residues that shifted significantly upon the addition of the ligand. The 
chemical shifts are very sensitive to the electronic environment of the nuclei. 
Therefore, perturbations in the chemical shift may not only be due to changes in the 
covalent molecular structure but also through non-covalent interaction with solvent 
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molecules and ligands. Chemical shifts are therefore a sensitive probe for the 
identification of the interaction surfaces of protein complexes. The chemical shifts 
that are perturbed usually belong to the residues that are closest to the interaction 
surface.  
It is important to understand that changes in the chemical shift merely imply the 
magnetic environment of the nuclei has changed, and are not necessarily due to a 
direct interaction with the ligand. If substantial structural rearrangement takes place in 
the protein through complex formation, wide spread chemical shift perturbations, may 
occur including residues that are distant from the actual site of interaction, but does 
experience a change in their structural environment. Therefore, it is important to take 
into account the accessible surface area of the protein in order to determine the 
interaction sites (Tien et al. 2013). The solvent accessibility of the residues was 
determined for the S100P molecule, and found that from the residues that 
significantly shifted, are also the ones that were accessible to the ligand. 
The most perturbed residues that were accessible to the solvent were determined to 
be 3Glu, 4Leu, 10Met, 16Ser, 17Arg, 26Gln, 43Gly, 86His, 89Phe, 90Glu, 91Lys, 
92Ala, 93Gly when the concentration of cromolyn to S100P was 2:1. The most 
perturbed residues that were accessible to the solvent were determined to be 3Glu, 
4Leu, 10Met, 17Arg, 23Gly, 43Gly, 56Lys, 86His, 89Phe, 90Glu, 91Lys, 92Ala, 
93Gly, and 94Leu when the concentration of cromolyn to S100P was 5:1. These 
residues were used as active residues in HADDOCK modelling analysis. The passive 
residues were defined by the HADDOCK program automatically, where all solvent 
accessible surface neighbours of the active residues were used.  The lowest energy 
conformations of the clusters generated by HADDOCK were analysed, and it showed 
that the cromolyn molecule was situated in the hydrophobic pocket of S100P. LigPlot 
was used to obtain a schematic representation of the residues that were involved in 
the interaction. There were hydrophobic interactions within cromolyn and the S100P 
at residues 5Glu, 8Met, 9Gly, 12Ile, 26Glu, 86His, 89Phe and 90Glu. There were 
some hydrogen bonds that were observed between the residues formed between the 
hydroxyl group of cromolyn and 6Thr, 9Met, 91Lys, 92Ala, and 93Gly. The interaction 
between the cromolyn and S100P (at a concentration ratio of 2:1 respectively) 
dominated by hydrophobic interactions. Similarly hydrophobic interactions within 
cromolyn and the S100P; at a concentration ratio 5:1 respectively, were 1Met, 5Glu, 
8Met, 9Gly, 88Try, 89Phe, 90Glu, 91Lys and 93Gly. Hydrogen bonds between were 
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formed between 6Thr, 26Gln and 94Leu and the hydroxyl group of cromolyn, except 
for one hydrogen bond with 26Gln, where the hydrogen bond was with the oxygen in 
the phenyl ring. The interaction between the cromolyn and S100P (at a concentration 
ratio of 5:1 respectively) is dominated by hydrophobic interactions. 
Similarly the other drug compounds assessed also had hydrophobic interactions 
dominating the interaction between S100P and ligand. A study that investigated the 
interactions between the calcium-bound S100P and the V domain of RAGE, reported 
that the binding of the S100P to the V domain of RAGE is stabilised by hydrophobic 
residues in the interface between S100P and the RAGE-V domain (Penumutchu, 
Chou et al. 2014b). In the present study it was found that the hydrophobic bonds 
dominate in the binding of the S100P to the ligands. This suggest that the residues 
involved in the binding of ligand to S100P are related to the residues in the binding 
interface of S100P to RAGE V domain. If the hydrophobic bonds between S100P and 
the ligand is stronger than hydrophobic bonds involved in S100P and V domain of 
RAGE receptor, those drugs compounds may serve a therapeutic use for treating 
S100P induced cancer.    
A study by Penumutchu et al., 2014a, mapped the interfacial residues on S100P and 
cromolyn contact surface by 1H-15N HSQC, therefore cromolyn was used as a 
positive control for studying the interaction sites by NMR. NMR characterisation of 
the binding interface between cromolyn and S100P demonstrated that the residues 
with significantly perturbed chemical shifts were the 3Glu, 4Leu, 5Glu, 10Met, 11Ile, 
12Ile, 14Val and 15Phe in the Helix-1 and 43Gly, 44Phe from the linker region and 
84Ala, 89Phe, and 93Gly from Helix-4. This study modelled the S100P-cromolyn 
complex, and the area to which cromolyn showed to have interactions in the present 
study was similar to the region with the cromolyn interacted in the study by 
Penumutchu et al 2014a. (Figures 9 and 11). Residues that are involved in the 
interaction were mapped onto the S100P dimer. It was observed that the residues 
that are involved in the interaction were located mainly in Helix-1 and Helix 4 at both 
2:1 and 5:1 cromolyn to S100P concentration. This suggests that cromolyn has a 
binding affinity towards the S100P. The structural characterisation of the complex 
S100P-RAGE using NMR, mutagenesis and functional assays reported that the 
RAGE V binding site is situated in the in the linker region and the Helix-1 and Helix-4. 
(Penumutchu, Chou et al. 2014a). The study also shows that the binding region of 
cromolyn (44Phe, 89Phe and 5Glu) is involved in S100P RAGE binding. This 
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suggests that if a ligand such as cromolyn binds to the S100P RAGE binding 
interface, S100P RAGE interaction could be blocked and therefore prevent the 
activation of the RAGE receptor via S100P. The present study also shows that the 
residues that are involved in the interaction with cromolyn to S100P includes the 
binding region residues (5Glu, 44Phe and 89Phe) mentioned in Penumutchu, Chou 
et al. 2014a. However since the binding constant of S100P-cromolyn was weak 
compared to S100P-RAGE, the blocking of the S100P through cromolyn might not be 
effective.  
The other ligands that were analysed by the NMR titration analysis also revealed 
interactions to S100P. The drug compound C72 interacted with the residues 44Phe, 
84Ala, 92Ala, 88Tyr, 93Gly, 85Cys, 87Lys, 91Lys and 90Glu. Residues that involved 
in the interaction were located to be at mainly in Helix-4 as demonstrated in Figure 14 
(A). This was a hydrophobic pocket of the S100P protein (Figure 14 (B)). According 
to the structural characterisation of the complex S100P-RAGE using NMR the RAGE 
V binding site is situated in the linker region and the Helix-1 and Helix-4. 
(Penumutchu, Chou et al. 2014b). This suggests that ligand C72 which has its 
binding site in Helix-4 is able to bind to the S100P and thereby block S100P from 
binding to RAGE receptor.  
Similarly binding regions of the other three ligand molecules analysed (IBS409, 
IBS798 and IBS863) also had binding sites in Helix 1, 4 and the linker region. 
Although all the ligands show interaction toward the S100P molecule, the strength of 
the binding would determine if these compounds are efficient to be used as drugs.  
4.3 Isothermal titration Calorimetry 
 The ITC assay was performed in order to assess the binding affinity and the 
stoichiometry of the S100P-ligand complexes, by determining the heat changes during 
the interaction. The initial experiments were performed with the ligands cromolyn and 
C72, but from these experiments showed very little or no binding was observed, and 
therefore binding parameters could not be determined. The ITC performed by using 
CaCl2 as a ligand, gave a protein to ligand binding stoichiometry of 1:4. This 
experiment with calcium titration was performed in order to use it as a reference. 
Figure 27 (B) shows the Wilmans plot of CaCl2 titration, where data was fitted a non-
linear least square approach to the ‘one set of sites’ site model. This yielded a 
dissociation constant of Kd = 6.62E5±0.52E5 µM with additional parameters of N = 4±0, 
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ΔH = -3988± 156.2 kcal/mol, and ΔS = 13.6 cal/mol/deg. The negative enthalpy of ΔH = -
3988 kcal/mol suggests that the reaction is exothermic (releasing heat), this is also 
shown by the negative peaks in Figure 27 (A). The stoichiometry of binding interaction 
was 1:4. This information is evident as there are 2 EF hands in the S100P protein. 
Each EF hand binds two Ca2+ ions, therefore four Ca2+ ions can bind to one molecule 
of S100P.  
 
4.4 Limitations 
It is important that the protein that is expressed and purified contains minimal 
impurities when used for NMR experimentation as traces of impurities in the 
sample may produce peaks in the NMR spectra. If these peaks are not identified as 
caused by impurity the spectra can be misinterpreted. This can lead to the 
assignment of an incorrect structure to the compound being studies. The protein 
expressed also contained a hexa-histidine tag, in order to use the HisTrap column 
in purification of protein by affinity chromatography. This histidine tag could be 
removed by thrombin cleavage of the tag (Koltzscher, Neumann et al. 2003). 
Additional purification of the sample may be achieved by size-exclusion 
chromatography (gel filtration) of the sample and if necessary a final ‘polishing’ step 
would be to use ion exchange chromatography. Gel filtration also has the ability of 
removing reducing agents as DTT from the sample that can interfere with the BCA 
protein concentration assay. 
The method of protein concentration calculation for this protein was by using the 
BCA assay. This assay had a compatible dye for reducing agents for reducing 
agents enabling it to be used with protein samples containing up to 5 mM DTT 
(Johnson, 2015). In the BCA assay, the protein concentration is determined by 
creating a standard curve from a standard protein (e. g: BSA), however if S100P 
does not interact with the BCA dye in a similar way as the standard protein, the 
concentration could be underestimated or overestimated. More accurate and 
quicker methods as measuring absorbance at 280nm cannot be performed as the 
S100P protein does not contain tryptophan residues (Johnson, 2015). The analysis 
of the stoichiometry by ITC highly depends on the accuracy of the concentration of 
the protein used. Therefore any inaccuracies in the protein concentration will be 
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affect the ITC data interpretation. One other limitations of ITC is that it requires a 
large amount of protein. 
4.5 Conclusion 
Previous studies by Arumugam et al 2006, that the anti-allergy drug cromolyn binds to 
S100P blocking it’s interaction with the RAGE receptor, and in this manner reduce the 
tumour growth and invasion of pancreatic cancer in mouse models. Therefore this 
suggested that ligand molecules that block S100P from binding and activating RAGE, 
to be effective as a therapeutic agent for pancreatic cancer. All the ligands, C72, 
IBS409, IBS798 and IBS863 showed interactions with S100P. Binding sites of the 
ligands were identified via NMR, and the binding was found to be dominated by 
hydrophobic interactions. Further ITC experimentation may be required in order to gain 
an understanding of the stoichiometry and the binding affinity for these ligands. 
4.6 Further work  
More compounds could be analysed and if strong binding indicated with one or 
more lead compounds, crystallisation trials of S100P in complex with these 
compounds may be conducted in order to obtain the three-dimensional structure of 
S100P in complex. The data that collected from this project may have implications 
for cancer drug discovery and ultimately lead on to further research on the effects 
in vivo, a potential patent and collaborations with other national/international 
research groups. 
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6 Appendix 1 
Table 2 Proposed values for ASA normalization (in Å), compared to previously used scales 
defined by Miller et al.(Tien, Meyer et al. 2013) 
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Table 3 Relative solvent accessibility calculated for each residue by using equation 2. The 
values highlighted in yellow are the relative solvent accessibility of ≥50% of the main chain 
were selected  
Residue 
 
Solvent 
accessible 
Surface area 
(Å2) 
Relative 
Solvent 
Accessibility 
(Å2) 
Relative 
Solvent 
Accessibility 
(%) 
1 184.33 0.904 90 
2 78.67 0.539 54 
3 161.53 0.883 88 
4 126.67 0.704 70 
5 82.13 0.449 45 
6 53.91 0.369 37 
7 42.5 0.376 38 
8 105.14 0.515 52 
9 28.58 0.336 34 
10 105.23 0.516 52 
11 44.28 0.243 24 
12 97 0.533 53 
13 59.46 0.394 39 
14 29.32 0.183 18 
15 12.29 0.056 6 
16 66.58 0.546 55 
17 167.56 0.695 70 
18 31.62 0.138 14 
19 1.58 0.013 1 
20 47.24 0.556 56 
21 99.26 0.814 81 
22 91.02 0.497 50 
23 65.1 0.766 77 
24 51.32 0.421 42 
25 92.53 0.634 63 
26 132.32 0.700 70 
27 14.26 0.098 10 
28 0 0.000 0 
29 27.17 0.186 19 
30 100.02 0.474 47 
31 35.58 0.419 42 
32 5.28 0.029 3 
33 0.76 0.004 0 
34 94.06 0.446 45 
35 68.65 0.429 43 
36 1.39 0.008 1 
37 2.55 0.013 1 
38 95.69 0.523 52 
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Residue 
 
Solvent 
accessible 
Surface area 
(Å2) 
Relative 
Solvent 
Accessibility 
(Å2) 
Relative 
Solvent 
Accessibility 
(%) 
39 145.18 0.688 69 
40 68.77 0.376 38 
41 50.33 0.280 28 
42 94.18 0.659 66 
43 78.68 0.926 93 
44 96.61 0.443 44 
45 86.83 0.482 48 
52 170.48 1.129 113 
53 44.22 0.391 39 
54 22.76 0.142 14 
55 44.49 0.295 29 
56 141.57 0.671 67 
57 13.12 0.073 7 
58 10.59 0.059 6 
59 138.99 0.659 66 
60 119.32 0.790 79 
61 26.74 0.149 15 
62 24.68 0.163 16 
63 91.94 0.814 81 
64 95.92 0.607 61 
65 65.29 0.768 77 
66 56.77 0.376 38 
67 65.09 0.576 58 
68 46.58 0.246 25 
69 0 0.000 0 
70 41.01 0.272 27 
71 63.96 0.293 29 
72 77.16 0.632 63 
73 14.66 0.080 8 
74 5.82 0.027 3 
75 59.78 0.328 33 
76 103.2 0.645 65 
77 13.95 0.064 6 
78 30.7 0.192 19 
79 56.78 0.502 50 
80 55.28 0.489 49 
81 40.91 0.225 22 
82 81.6 0.559 56 
83 58.61 0.480 48 
84 57.98 0.513 51 
85 67.2 0.480 48 
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Residue 
 
Solvent 
accessible 
Surface area 
(Å2) 
Relative 
Solvent 
Accessibility 
(Å2) 
Relative 
Solvent 
Accessibility 
(%) 
86 131.07 0.676 68 
87 121.16 0.574 57 
88 148.55 0.649 65 
89 140.76 0.646 65 
90 103.72 0.567 57 
91 129.92 0.616 62 
92 75.87 0.671 67 
93 58.25 0.685 69 
94 208.03 1.156 116 
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7 Appendix 2 
 
 
Figure 28(A) Overlay of the 15N-1H HSQC spectra of 0.42 mM 15N-labeled S100P (black) and in 
the complex form with 0.84 mM of the IBS409 (magenta), are shown. (B) Bar graph of the 
weighted average of the chemical shift (1H and 15N) variations of the amino acid residues in the 
S100P–IBS409 adduct at concentration ratio 2:1, IBS409 to S100P respectively. The black 
dashed line represents the average chemical shift perturbation (Δppm ≥ 0.02 ppm) 
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Figure 29: (A) Overlay of the 15N-1H HSQC spectra of 0.42 mM 15N-labeled S100P (black) and 
in the complex form with 2.02 mM of the IBS409 (magenta), are shown. (B) Bar graph of the 
weighted average of the chemical shift (1H and 15N) variations of the amino acid residues in the 
S100P–IBS409 adduct at concentration ratio 5:1, IBS409 to S100P respectively. The black 
dashed line represents the average chemical shift perturbation (Δppm ≥ 0.029 ppm) 
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8 Appendix 3 
.
 
 
Figure 30: (A) Overlay of the 15N-1H HSQC spectra of 0.42 mM 15N-labeled S100P (black) and 
in the complex form with 0.84 mM of the IBS798 (orange), are shown. (B) Bar graph of the 
weighted average of the chemical shift (1H and 15N) variations of the amino acid residues in the 
S100P–IBS798 adduct at concentration ratio 2:1, IBS798 to S100P respectively. The black 
dashed line represents the average chemical shift perturbation (Δppm ≥ 0.018 ppm).
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Figure 31: (A) Overlay of the 15N-1H HSQC spectra of 0.42 mM 15N-labeled S100P (black) and 
in the complex form with 2.02 mM of the IBS798 (orange), are shown. (B) Bar graph of the 
weighted average of the chemical shift (1H and 15N) variations of the amino acid residues in the 
S100P–IBS798 adduct at concentration ratio 5:1, IBS798 to S100P respectively. The black 
dashed line represents the average chemical shift perturbation (Δppm>0.018 ppm). 
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9 Appendix 4 
 
 
Figure 32: (A) Overlay of the 15N-1H HSQC spectra of 0.42 mM 15N-labeled S100P (black) and 
in the complex form with 0.84 mM of the IBS863 (red), are shown. (B) Bar graph of the 
weighted average of the chemical shift (1H and 15N) variations of the amino acid residues in the 
S100P–IBS863 adduct at concentration ratio 2:1, IBS863 to S100P respectively. The black 
dashed line represents the average chemical shift perturbation (Δppm ≥0.008 ppm). 
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Figure 33: (A) Overlay of the 15N-1H HSQC spectra of 0.42 mM 15N-labeled S100P (black) and 
in the complex form with 2.02 mM of the IBS863 (red), are shown. (B) Bar graph of the 
weighted average of the chemical shift (1H and 15N) variations of the amino acid residues in the 
S100P–IBS863 adduct at concentration ratio 5:1, IBS863 to S100P respectively. The black 
dashed line represents the average chemical shift perturbation (Δppm > 0.008 ppm) 
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10 Appendix 5 
 
Figure 34 The ITC titration of cromolyn to S100P. (A) Raw data of the ITC titration with 
cromolyn. (B) The Wilmans plot of cromolyn titration, Very little or no binding was observed, and 
therefore binding parameters could not be determined. 
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Figure 35 The ITC titration of C72 to S100P (A) Raw data of the ITC titration with C72. (B) 
The Wilmans plot of C72 titration, Very little or no binding was observed, and therefore binding 
parameters could not be determined. 
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11 Appendix 6 
11.1 Control of Substances Hazardous to Health (COSHH) Assessment 
 
       
    
          
ACTIVITY INFORMATION 
Name of Assessor/Contact 
details 
Name:Thamarasi Kekule Vithanage 
Email address: thamarasivithana@ymail.com 
Ext no: 
Title of Activity 
 
 
Protein Purification 
Location of Activity 
 
 
CP Snow Building  
Description of Activity 
 
 
Preparation of cell lysate by sonication. 
Protein purification by Ni-affinity chromatography. 
Personnel Involved 
 
 
Staff members, Students 
 
 
HAZARD CLASSIFICATION 
Hazards involved in project. 
 
 
 
□ Harmful/Irritant                            
 
 
□ Corrosive      
  
□  Radioactive    
 
□    Biological 
 
□ Toxic                                       
 
 
□ Health Hazard      
                  
□   Explosive   
 
□  Oxidising 
 
□ Flammable   
        
□ Hazardous to the 
Environment 
□    Gas under 
pressure 
 
   Ref No:  
Date:  
Review Date:  
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Severity Classification 
 
Harmful/Irritant    2   
                              
Corrosive              3                                Radioactive         * Biological             ** 
Toxic                   3 
 
Health Hazard      4 
 
Explosive               5          Oxidising              5 
Flammable          3                                Hazardous to the 
Environment         4 
 
Gas under pressure 
                               5 
 
 
*   Radioactive – If any work will involve use of Radioactivity contact the Radiation Protection 
Supervisor, Janet Evans (ext 4379, j.s.evans@herts.ac.uk) for an accurate severity classification 
before work begins. 
 
** Biological – If any work will involve using biological samples or suspected biohazards contact the 
Biological Safety Advisor.  
      For Department of Human and Environmental Sciences contact   Di Francis   (ext 4527, 
d.l.francis@herts.ac.uk). 
      For Department of Pharmacy contact   James Stanley (ext 4599, j.k.stanley@herts.ac.uk). 
 
 
Substance 
Used or 
Produced. 
Concentratio
n or amount 
used. 
Hazard  
Words and Pictograms 
Route of 
Entry 
Severity 
 
DTT 
(Dithiothreitol) 
 
Stock 1M -> 
1-10mm final 
Harmful/Irrtant 
Ingestion 
Inhalation 
Skin 
Eye 
2 
 
Human S100P 
gene in 
PET28 
plasmid 
 
 Not Hazardous Ingestion 
Inhalation 
Skin 
Eye 
1 
 
Na2HPO4 
(Disodium 
Hydrogen 
Phosphate) 
 
 Not Hazardous Ingestion 
Inhalation 
Skin 
Eye 
1 
 
NaH2PO4 
(Sodium 
Dihydrogen 
Phosphate / 
Orthophospha
te) 
 
 Not Hazardous  Ingestion 
Inhalation 
Skin 
Eye 
1 
 
NaCl 
(Sodium 
Chloride) 
Stock 5M-> 
50- 500mm 
Not hazadrous Ingestion 
Inhalation 
Skin 
Eye 
1 
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Tris 
 
Stock: 
1.5/2M -> 
20nm 
 
Not Hazardous 
Ingestion 
Inhalation 
Skin 
Eye 
 
1 
 
HCl 
(Hydrochloric 
Acid) 
<10ml  
 Harmful/Irritant Corrosive 
Ingestion 
Inhalation 
Skin 
Eye 
 
3 
 
EDTA 
(Ethylenediam
inetetraacetic 
acid) 
Stock : 0.5M 
-> 5-50mM 
 Harmful/Irritant 
 
Eye 
 
2 
 
MES 
 
2-(N-
Morpholino)et
hanesulfonic 
acid sodium 
salt 
 
  
Not Hazardous 
 
Ingestion 
Inhalation 
Skin 
Eye 
 
1 
HisTrap™ HP, 
5 ml, 5 x 5 ml 
(Catalogue 
number : 17-
5248-02) 
 
Flammable 
Ingestion 
Inhalation 
Skin 
Eye 
3 
NaOH 
(Sodium 
Hydroxide) 
 
Corrosive 
Skin 
Eye 
3 
Imidazole Stock 2M -> 
20- 50mm 
Harmful/Irrtant Corrosive 
Health hazard 
 
Ingestion 
Inhalation 
Skin 
Eye 
4 
Triton X-100 1% 
Harmful/Irrtant Corrosive 
Ingestion 
Inhalation 
Skin 
Eye 
3 
NiCl2 (Nickel 
Chloride) 
 
Health hazard 
Harmful/Irrtant  Hazardous to the 
Environment          
 
Ingestion 
Inhalation 
Skin 
Eye 
4 
Information 
sources (eg 
MSDS) 
MSDS (SIGMA – ALDRICH) and GE HealthCare 
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CONTROL MEASURES 
Additional measures to be used over and above local codes of practice and local rules. 
Keep away from heat/sparks/open flames/hot surfaces. – No smoking. 
Avoid exposure – obtain special instructions before use. Avoid contact with skin and eyes. Avoid 
formation of dust and aerosols. 
Provide appropriate exhaust ventilation at places where dust is formed. 
 
 
Are alternative less hazardous substances available? If so please list below and state why they 
cannot be used. 
 
NO 
 
EMERGENCY AND DISPOSAL PROCEDURES 
Measures to be taken in case of Spillage or Uncontrolled release 
Solid spill: 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
 
Liquid Spill: 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable closed 
containers for disposal. 
Contain spillage, and then collect an electrically protected vacuum cleaner or wet –brushing and 
place in container for disposal according to local regulations  
 
Disposal Measures 
 
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in 
igniting, as this material is highly flammable. Offer surplus and non-recyclable solutions to a 
licensed disposal company 
NiCl2; Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix 
the material with a combustible solvent and burn in a chemical incinerator equipped with an 
afterburner and scrubber. 
Measures to be taken in case of Fire 
Types of fire extinguisher to be used: 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide 
Do not use water jet. 
 
Emergency procedure in case of fire: 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate 
ventilation. Remove all sources of ignition. Evacuate personal in areas. Beware of vapours 
accumulating to form explosive concentration. Vapours can accumulate in low areas. 
 
Toxic fumes emitted under fire conditions: 
Carbon oxides, Iron oxides, Oxides of phosphorus, Sodium oxides, Nitrogen oxides, Hydrogen 
cyanide 
Measures to be taken for First Aid 
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General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance. 
 In contact with eyes: 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.  
In contact with skin: 
Wash off soap and plenty of water. Consult a physician. 
If inhaled: 
If breathed in, move person into fresh air. If not breathing give artificial respiration. Consult a 
physician. 
If ingested: 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth 
with water. Consult a physician. Immediately call a POISON CENTER or doctor/  
physician 
 
Signs and symptoms of exposure: 
HCL; Burning sensation, cough, wheezing, laryngitis, short of breath, spasm, inflammation and 
oedema of larynx, spasm, inflammation and oedema of the bronchi, pneumonitis, pulmonary 
oedema,  material is extremely destructive to tissue of the mucous membranes and upper 
respiratory tract, eyes and skin. 
NiCl2; Substances that can cause occupational asthma (also known as asthmagens and respiratory 
sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, 
irritant  
or other mechanisms. These symptoms can range in severity from a runny nose to asthma. 
 
Is hospitalisation required? Yes 
 
Persons at Special Risk: Pregnancy, Asthma patients 
 
  
- 90 - 
 
 
 
       
    
          
ACTIVITY INFORMATION 
Name of Assessor/Contact 
details 
Name:Thamarasi Kekule Vithanage 
Email address:thamarasivithana@ymail.com 
Ext no: 
Title of Activity 
 
 
Bacterial transformation and protein expression 
Location of Activity 
 
 
C.P Snow Building  
Description of Activity 
 
 
Transformation of competent E.coli with plasmid constructs for 
S100P protein formation. 
Induction of protein expression using IPTG 
Personnel Involved 
 
 
Staff members, students 
 
 
HAZARD CLASSIFICATION 
Hazards involved in project. 
 
 
 
□ Harmful/Irritant                            
 
 
□ Corrosive      
  
□  Radioactive    
 
□    Biological 
 
□ Toxic                                       
 
 
□ Health Hazard      
                  
□   Explosive   
 
□  Oxidising 
 
□ Flammable   
        
 
 
□ Hazardous to the 
Environment 
 
□    Gas under 
pressure 
 
 
 
 
   Ref No:  
Date:  
Review Date:  
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Severity Classification 
 
Harmful/Irritant    2   
                              
Corrosive              3                                Radioactive         * Biological             ** 
Toxic                   3 
 
Health Hazard      4 
 
Explosive               5          Oxidising              5 
Flammable          3                                Hazardous to the 
Environment         4 
 
Gas under pressure 
                               5 
 
 
*   Radioactive – If any work will involve use of Radioactivity contact the Radiation Protection 
Supervisor, Janet Evans (ext 4379, j.s.evans@herts.ac.uk) for an accurate severity classification 
before work begins. 
 
** Biological – If any work will involve using biological samples or suspected biohazards contact the 
Biological Safety Advisor.  
      For Department of Human and Environmental Sciences contact   Di Francis   (ext 4527, 
d.l.francis@herts.ac.uk). 
      For Department of Pharmacy contact   James Stanley (ext 4599, j.k.stanley@herts.ac.uk). 
 
 
Substance 
Used or 
Produced. 
Concentration 
or amount 
used. 
Hazard  
Words and Pictograms 
Route of 
Entry 
Severity 
 
Escherichia 
coli 
 
 
 
 Biological 
Ingestion  
Inhalation 
Skin 
Eye 
 
2 
Human 
S100P gene 
in PET28 
plasmid 
 
  
Not Hazardous  
Ingestion 
Inhalation 
Skin 
Eye 
 
1 
LB (Luria 
Bertani 
Broth) 
 Not Hazardous Ingestion 
Inhalation 
Skin 
Eye 
 
1 
Tryptone  Not Hazardous Ingestion 
Inhalation 
Skin 
Eye 
1 
Yeast 
Extract 
 Not Hazardous Ingestion 
Inhalation 
Skin 
Eye 
1 
NaCl  Not Hazardous Ingestion 
Inhalation 
Skin 
Eye 
1 
Agar  Not Hazardous Ingestion 
Inhalation 
Skin 
Eye 
1 
Kanamycin Stock: 34mg/ml 
-> 34 µg/ml 
final 
concentration 
Not Hazardous Ingestion 
Inhalation 
Skin 
Eye 
1 
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Ampicillin  Stock: 
150mg/ml -> 
100 µg/ml final 
concentration 
Harmful/Irrtant Health 
hazard 
 
Ingestion 
Inhalation 
Skin 
Eye 
4 
IPTG 
(Isopropyl β-
D-1-
thiogalactop
yranoside) 
Stock: 1M -> 
<2mM final 
concentration Flammable Toxic 
Health hazard 
Ingestion 
Inhalation 
Skin 
Eye 
4 
Information 
sources (eg 
MSDS) 
MSDS (SIGMA – ALDRICH) 
 
CONTROL MEASURES 
Additional measures to be used over and above local codes of practice and local rules. 
Provide appropriate exhaust ventilation at place where dust is formed. 
Keep away from heat/sparks/open flames/ hot surfaces. – No smoking. 
Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. 
 
 
Are alternative less hazardous substances available? If so please list below and state why they 
cannot be used. 
NO 
 
 
EMERGENCY AND DISPOSAL PROCEDURES 
Measures to be taken in case of Spillage or Uncontrolled release 
Solid spill: 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed 
containers for disposal 
 
Liquid Spill: 
 
Soak up with inert absorbent material and dispose of a hazardous waste. Keep in suitable, closed 
containers for disposal 
Disposal Measures 
 
Offer surplus and non-recyclable solutions to a licenced disposal company. Dissolve or mix the 
material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner 
and scrubber.  
 
Measures to be taken in case of Fire 
Types of fire extinguisher to be used: 
Use water spray, alcohol- resistant foam, dry chemical or Carbon dioxide 
 
Emergency procedure in case of fire: 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. 
Ensure adequate ventilation.  
Evacuate personal to safe areas. 
 
Toxic fumes emitted under fire conditions: 
Carbon oxides, Nitrogen oxides, Hydrogen chloride gas, Sulphur oxides, Sodium oxides 
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Measures to be taken for First Aid 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance. 
In contact with eyes: 
Rinse thoroughly with plenty of water at least 15minutes and consult a physician. 
In contact with skin: 
Take off contaminated clothes and shoes immediately. Wash off with soap and plenty of water. 
If inhaled: 
If breathed in, move person to fresh air. If not breathing, give artificial respiration. Consult a 
physician.  
If ingested: 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth 
with water. Consult a physician. If experiencing respiratory symptoms: Call a POISON CENTER or 
doctor/  
physician. 
 
Signs and symptoms of exposure: 
IPTG; Nausea, dizziness, gastrointestinal disturbance, weakness, confusion, drowsiness, 
unconsciousness. 
Is hospitalisation required? Yes 
 
Persons at Special Risk: No data available. 
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ACTIVITY INFORMATION 
Name of Assessor/Contact 
details 
Name:Thamarasi Kekule Vithanage 
Email address:thamarasivithana@ymail.com 
Ext no: 
Title of Activity 
 
 
SDS- PAGE 
Location of Activity 
 
 
C.P Snow Building  
Description of Activity 
 
 
SDS-PAGE analysis of recombinant proteins 
Personnel Involved 
 
 
Staff members, students 
 
 
HAZARD CLASSIFICATION 
Hazards involved in project. 
 
 
 
□ Harmful/Irritant                            
 
 
□ Corrosive      
  
□  Radioactive    
 
□    Biological 
 
□ Toxic                                       
 
 
□ Health Hazard      
                  
□   Explosive   
 
□  Oxidising 
 
□ Flammable   
        
 
 
□ Hazardous to the 
Environment 
 
□    Gas under 
pressure 
 
 
 
 
   Ref No:  
Date:  
Review Date:  
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Severity Classification 
 
Harmful/Irritant    2   
                              
Corrosive              3                                Radioactive         * Biological             ** 
Toxic                   3 
 
Health Hazard      4 
 
Explosive               5          Oxidising              5 
Flammable          3                                Hazardous to the 
Environment         4 
 
Gas under pressure 
                               5 
 
 
*   Radioactive – If any work will involve use of Radioactivity contact the Radiation Protection 
Supervisor, Janet Evans (ext 4379, j.s.evans@herts.ac.uk) for an accurate severity classification 
before work begins. 
 
** Biological – If any work will involve using biological samples or suspected biohazards contact the 
Biological Safety Advisor.  
      For Department of Human and Environmental Sciences contact   Di Francis   (ext 4527, 
d.l.francis@herts.ac.uk). 
      For Department of Pharmacy contact   James Stanley (ext 4599, j.k.stanley@herts.ac.uk). 
 
 
Substance 
Used or 
Produced. 
Concentration 
or amount 
used. 
Hazard  
Words and Pictograms 
Route of 
Entry 
Severity 
 
Tris 
 
  
Not Hazardous 
Ingestion 
Inhalation 
Skin 
Eye 
 
1 
 
HCl 
(Hydrochlori
c acid) 
  
 Harmful/Irritant Corrosive 
Ingestion 
Inhalation 
Skin 
Eye 
 
3 
 
Acrylamide 
 
  
Toxic  Health Hazard 
Ingestion 
Inhalation 
Skin 
Eye 
 
4 
TEMED 
(1,2-
Bis(dimethyl
amino)ethan
) 
 
Flammable Harmful/Irritant 
Corrosive 
Ingestion 
Inhalation 
Skin 
Eye 
3 
APS 
(Ammonium 
persulfate) 
 
Flammable Harmful/Irritant 
 Health Hazard 
 
Ingestion 
Inhalation 
Skin 
Eye 
4 
SDS 
(Sodium 
Dodecyl 
Sulphate) 
 
Flammable Harmful/Irritant 
Ingestion 
Inhalation 
Skin 
Eye 
 
3 
Glycine  Not Hazardous  Ingestion 
Inhalation 
1 
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Skin 
Eye 
Glycerol   Not Hazardous  Ingestion 
Inhalation 
Skin 
Eye 
1 
Bromophen
ol blue 
 Not Hazardous  Ingestion 
Inhalation 
Skin 
Eye 
1 
DTT 
(Dithiothreit
ol) 
 
 
Harmful/Irritant 
Ingestion 
Inhalation 
Skin 
Eye 
2 
Coomassie 
brilliant blue 
 Not Hazardous  Ingestion 
Inhalation 
Skin 
Eye 
1 
Methanol  
Flammable Toxic  
 Health Hazard 
Ingestion 
Inhalation 
Skin 
Eye 
4 
Glacial 
acetic acid 
 
Flammable Corrosive 
Ingestion 
Inhalation 
Skin 
Eye 
3 
Information 
sources (eg 
MSDS) 
MSDS (SIGMA – ALDRICH) 
  
 
CONTROL MEASURES 
Additional measures to be used over and above local codes of practice and local rules. 
Keep away from heat/sparks/open flames/ hot surfaces. – No smoking. 
Keep/Store away from clothing combustible materials 
Provide appropriate exhaust ventilation at place where dust is formed. 
Avoid breathe dust/ fume/ gas/ mist/ vapours/ spray. 
 
Are alternative less hazardous substances available? If so please list below and state why they 
cannot be used. 
NO 
 
EMERGENCY AND DISPOSAL PROCEDURES 
Measures to be taken in case of Spillage or Uncontrolled release 
Avoid dust formation. Avoid breathing vapours, mist or gas 
Sweep up and shovel. Keep in suitable, closed containers for disposal 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains 
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing 
and place in container for disposal according to local regulations 
 
Disposal Measures 
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Burn in a chemical incinerator equipped with an after burner and scrubber but exert extra care in 
igniting as this material is highly flammable. Offer surplus and non-recyclable solutions to a 
licensed disposal company. 
 
Measures to be taken in case of Fire 
Types of fire extinguisher to be used: 
Use water spray, alcohol- resistant foam, dry chemical or Carbon dioxide 
 
Emergency procedure in case of fire: 
Wear self-contained breathing apparatus for firefighting if necessary 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate 
ventilation. Remove all sources of ignition. Evacuate personal to safe areas. Beware of vapours 
accumulating to form explosive concentrations. Vapours can accumulate in low areas 
 
Toxic fumes emitted under fire conditions: 
Carbon oxides, Nitrogen oxides, Hydrogen bromide gas, Sulphur oxides 
Measures to be taken for First Aid 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance. 
In contact with eyes: 
Rinse thoroughly with plenty of water at least 15minutes and consult a physician. 
In contact with skin: 
Take off contaminated clothes and shoes immediately. Wash off with soap and plenty of water. 
Take victim immediately to hospital. Consult a physician.  
If inhaled: 
If breathed in, move person to fresh air. If not breathing, give artificial respiration. Consult a 
physician.  
If ingested: 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth 
with water. Consult a physician. 
 
Signs and symptoms of exposure: 
TEMED; Material is extremely destructive to tissue of the mucous membranes and upper 
respiratory tract, eyes and skin, spasm, inflammation and oedema of the larynx, spasm, 
inflammation and oedema of the bronchi, pneumonitis, pulmonary oedema 
SDS; Sneezing, the sodium salt of dodecyl sulphate has been reported to cause pulmonary 
sensitization resulting in hyperactive airway dysfunction and pulmonary allergy accompanied by 
fatigue, malaise, and aching. 
DTT; Nausea, Headache, Vomiting, Central nervous system depression. 
Methanol; Headache, Dizziness, Drowsiness, Metabolic acidosis, Coma, Seizures. 
Glacial acetic acid; Spasm, inflammation and oedema, burning sensation, cough, wheezing, 
laryngitis, shortness of breath, headache, nausea, vomiting , ingestion or inhalation of concentrated 
acetic acid causes damage to tissues of respiratory and digestive tracts 
Symptoms include: haematuria, anuria, uraemia, albuminuria, haemolysis, convulsions, bronchitis, 
pulmonary oedema, pneumonia, cardiovascular collapse, shock, and death. Direct contact or 
exposure to high concentration of vapour with skin or eyes can cause: erythema, blisters, tissue 
destruction with slow healing, skin blackening, hyperkeratosis, fissures, corneal erosion, 
opacification, iritis, conjunctivitis, and possible blindness 
Is hospitalisation required? Yes 
 
Persons at Special Risk: Pregnancy, Asthma, Allergy. 
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ACTIVITY INFORMATION 
Name of Assessor/Contact 
details 
Name:Thamarasi Kekule Vithanage 
Email address:thamarasivithana@ymail.com 
Ext no: 
Title of Activity 
 
 
Bradford assay or BCA assay 
Location of Activity 
 
 
C.P Snow Building  
Description of Activity 
 
 
Protein quantification  
Personnel Involved 
 
 
Staff members, students 
 
 
HAZARD CLASSIFICATION 
Hazards involved in project. 
 
 
 
□ Harmful/Irritant                            
 
 
□ Corrosive      
  
□  Radioactive    
 
□    Biological 
 
□ Toxic                                       
 
 
□ Health Hazard      
                  
□   Explosive   
 
□  Oxidising 
 
□ Flammable   
        
 
 
□ Hazardous to the 
Environment 
 
□    Gas under 
pressure 
 
 
 
 
   Ref No:  
Date:  
Review Date:  
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Severity Classification 
 
Harmful/Irritant    2   
                              
Corrosive              3                                Radioactive         * Biological             ** 
Toxic                   3 
 
Health Hazard      4 
 
Explosive               5          Oxidising              5 
Flammable          3                                Hazardous to the 
Environment         4 
 
Gas under pressure 
                               5 
 
 
*   Radioactive – If any work will involve use of Radioactivity contact the Radiation Protection 
Supervisor, Janet Evans (ext 4379, j.s.evans@herts.ac.uk) for an accurate severity classification 
before work begins. 
 
** Biological – If any work will involve using biological samples or suspected biohazards contact the 
Biological Safety Advisor.  
      For Department of Human and Environmental Sciences contact   Di Francis   (ext 4527, 
d.l.francis@herts.ac.uk). 
      For Department of Pharmacy contact   James Stanley (ext 4599, j.k.stanley@herts.ac.uk). 
 
 
Substance 
Used or 
Produced. 
Concentration 
or amount 
used. 
Hazard  
Words and Pictograms 
Route of 
Entry 
Severity 
 
Bradford 
reagent 
 
Corrosive Flammable 
Health Hazard 
Harmful/Irritant 
Ingestion  
Inhalation 
Skin 
Eye 
 
4 
BCA Reagent 
A 
Sodium 
carbonate 
[2,2’Biquinolin
e]-
4,4’dicarboxyl
ic acid, 
sodium salt 
(2:1) 
 
~ 
 
 
 
 
 
 
 
 
 
 
 
 
 
May cause irritation to respiratory system 
Ingestion  
Inhalation 
Skin 
Eye  
2 
BCA : 
Reagent B 
Copper (II) 
sulphate, 
Pentahydrate 
(1:1:5) 
 
 
May cause irritation to respiratory system 
Ingestion  
Inhalation 
Skin 
Eye 
2 
BCA 
Reconstituti
on buffer  
  
Not Hazardous 
Ingestion 
Inhalation 
Skin 
Eye 
1 
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BCA Assay 
Compatibilit
y Reagent 
 
 Health Hazard 
Toxic 
 
Ingestion 
Inhalation 
Skin 
Eye 
4 
 
BSA 
 
  
Not Hazardous 
Ingestion 
Inhalation 
Skin 
Eye 
 
1 
Information 
sources (eg 
MSDS) 
MSDS (SIGMA 
– ALDRICH) 
   
     
  
  
 
CONTROL MEASURES 
Additional measures to be used over and above local codes of practice and local rules. 
Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. 
Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating 
to form explosive concentrations. Vapours can accumulate in low areas. 
 
Are alternative less hazardous substances available? If so please list below and state why they 
cannot be used. 
NO 
 
 
EMERGENCY AND DISPOSAL PROCEDURES 
Measures to be taken in case of Spillage or Uncontrolled release 
Soak up with inert absorbent material and dispose of a hazardous waste. Keep in suitable, closed 
containers for disposal 
Disposal Measures 
 
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in 
igniting, as this material is highly flammable. Other surplus and non-recyclable solutions to be 
licenced disposal company. 
Measures to be taken in case of Fire 
Types of fire extinguisher to be used: 
Use water spray, alcohol- resistant foam, dry chemical or Carbon dioxide 
 
Emergency procedure in case of fire: 
Wear respiratory protection.  Avoid breathing vapours, mist or gas. Ensure adequate ventilation.  
Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating 
to form explosive concentrations. Vapours accumulate in low areas. 
 
Toxic fumes emitted under fire conditions: 
Toxic fumes of phosphorus oxides and/or phosphine, Carbon oxides, Oxides of phosphorus 
 
Measures to be taken for First Aid 
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General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance. 
In contact with eyes: 
Rinse thoroughly with plenty of water at least 15minutes and consult a physician. 
In contact with skin: 
Take off contaminated clothes and shoes immediately. Wash off with soap and plenty of water. 
Take victim immediately to hospital. Consult a physician. 
If inhaled: 
If breathed in, move person to fresh air. If not breathing, give artificial respiration. Consult a 
physician.  
If ingested: 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth 
with water. Consult a physician. 
 
Signs and symptoms of exposure: 
Methanol in Bradford Reagent; Headache, Dizziness, Drowsiness, Metabolic acidosis, Coma, 
Seizures. 
Acetic acid; Spasm, inflammation and oedema, burning sensation, cough, wheezing, laryngitis, 
shortness of breath, headache, nausea, vomiting , ingestion or inhalation of concentrated acetic 
acid causes damage to tissues of respiratory and digestive tracts 
Symptoms include: hematemesis, bloody diarrhoea, oedema and or perforation of the oesophagus 
and pylorus, pancreatitis, haematuria, anuria, uraemia, albuminuria, haemolysis, convulsions, 
bronchitis, pulmonary oedema, pneumonia, cardiovascular collapse, shock, and death. Direct 
contact or exposure to high concentration of vapour with skin or eyes can cause: erythema, 
blisters, tissue destruction with slow healing, skin blackening, hyperkeratosis, fissures, corneal 
erosion, opacification, iritis, conjunctivitis, and possible blindness 
H3PO4 in Bradford Reagent; Material is extremely destructive to tissue of the mucous membranes 
and the upper respiratory tract, eyes, and skin, spasm inflammation and oedema of the larynx, 
spasm, inflammation and oedema of the bronchi, pneumonitis, pulmonary oedema, burning 
sensation, cough, wheezing, laryngitis, shortness of breath, headache, nausea 
Is hospitalisation required? Yes 
 
Persons at Special Risk: No data available. 
 
 
 
 SIGNATURES 
 
 Staff/PhD student/MSc 
student/Undergraduate 
Name (Print) Signature Date 
Assessor 
 
    
Supervisor 
(if Assessor is a 
student) 
    
Local health and 
safety advisor / 
Laboratory 
Manager 
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11.2 Risk Assessment 
 
 
 
 
ACTIVITY INFORMATION 
 
Name of Assessor/ 
Contact details 
Name: Thamarasi Kekule Vithanage 
Email address: thamarasivithana@ymail.com 
Ext no: 
Title of Activity 
 
 
To follow a drug discovery cascade to identify the lead compound for S100P 
binding. 
Location of Activity 
 
 
CP Snow Building 
Description of Activity 
 
 
The competent E.coli cells will be transformed with plasmid constructs for 
the S100P protein formation. Then they grow in LB medium and induce 
protein expression using IPTG, protein purification using Ni affinity 
chromatography. Identification and characterisation of the proteins will be 
achieved using SDS-PAGE. 
Personnel Involved 
 
 
Staff Members, students 
 
 
TYPES OF HAZARD LIKELY TO BE ENCOUNTERED 
 
 Animal Allergens                                      
 .Biological Agents (see 
COSHH) 
 .Chemical Compounds 
(see CoSHH) 
 .Compressed/liquefied 
gases 
 Computers 
 .Electricity 
 Falling Objects 
 Farm Machinery 
 .Fire 
 .Glassware Handling 
 
 .Hand Tools 
 Ionising Radiation 
 Office Equipment 
 .Laboratory Equipment 
 Ladders 
 Manual Handling 
 Non-ionising Radiation 
 .Hot or cold extremes 
 Repetitive Handling 
 Severe Weather 
 Sharps 
 .Slips/trips/falls 
 Stress 
 Travel 
 Vacuum systems 
 Pressure systems 
 Vehicles 
 Violence, physical 
or verbal abuse 
 Workshop 
Machinery 
The above is not an exhaustive list – all other hazards should be listed here. 
 
Ref No:  
Date:  
Review Date:  
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HAZARD ASSESSMENT 
 
Severity of 
Consequences 
Factor Risk Classification 
No or minor injury/ health 
disorder 
Minor Damage or Loss 
Insignificant 
Environmental Impact 
Group 1 Biological 
agents 
1 Trivial 
(1) 
Trivial 
(2) 
Trivial 
(3) 
Trivial 
(4) 
Tolerable 
(5) 
Injury or Health Disorder 
– resulting in absence up 
to 3 days 
Moderate Damage or 
Loss 
Moderate Environmental 
Impact 
Group 2 Biological 
agents 
2 Trivial 
(2) 
Trivial 
(4) 
Tolerable 
(6) 
Tolerable 
(8) 
Moderate 
(10) 
Injury or Health Disorder 
–  
resulting in absence over 
3 days 
Substantial Damage or 
Loss 
Serious Environmental 
Impact 
Group 3 Biological 
agents 
3 Trivial 
(3) 
Tolerable 
(6) 
Moderate 
(9) 
Moderate 
(12) 
Substantial 
(15) 
 
Long Term Injury or 
Sickness – resulting in 
permanent incapacity 
Extensive Damage or 
Loss 
Major Long Term 
Environmental Impact  
 
4 Trivial 
(4) 
Tolerable 
(8) 
Moderate 
(12) 
Substantial 
(16) 
Intolerable 
(20) 
Death 
Serious Structural 
Damage 
Environmental 
Catastrophe 
Group 4 Biological 
agents 
5 Tolerable 
(5) 
Moderate 
(10) 
Substantial 
(15) 
Intolerable 
(20) 
Intolerable 
(25) 
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Note on Risk 
Classification: 
 
1-4         Trivial 
5-7         Tolerable 
8-12       Moderate 
13-16     Substantial 
>20         Intolerable 
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ASSESSMENT OF RISK CLASSIFICATION 
 
Hazard Likelihood Score Severity Score Risk Classification 
Chemical compunds 
 
2 4 8 
Biological agents 
 
2 2 4 
Laboratory equipment esp. 
Bunsen burners, glassware 
2 3 6 
Electric Hazard 
(electrophoresis) 
2 1 2 
Burn hazard 2 1 2 
Escherichia coli 2 2 4 
Ampicillin 1 4 4 
IPTG 
(Isopropyl β-D-1-
thiogalactopyranoside) 
2 4 8 
DTT 
(Dithiothreitol) 
 
2 2 4 
HCl 
(Hydrochloric Acid) 
2 3 6 
EDTA 
(Ethylenediaminetetraacetic 
acid) 
2 2 4 
HisTrap™ HP, 5 ml, 5 x 5 
ml (Catalogue number : 17-
5248-02) 
1 3 3 
NaOH 
(Sodium Hydroxide) 
2 3 6 
Imidazole 2 4 8 
Triton X-100 2 4 8 
NiCl2 (Nickel Chloride) 2 4 8 
Bradford reagent 1 4 4 
BCA Reagent A 2 2 4 
BCA Reagent B 2 2 4 
BCA Compatibility reagent  4 2 8 
Acrylamide 
 
1 4 4 
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EFFECT OF RISK CLASSIFICATION 
Risk Classification Action 
Trivial  No further action required. Activity can begin. 
Tolerable No additional controls required. Current controls must be maintained and 
monitored. 
Moderate Reduce risks if cost effective. Implement new controls over an agreed 
period. 
Substantial Activity cannot begin without major risk reduction. 
Intolerable Activity must not begin. 
 
RISK CONTROL MEASURES 
 
 
Is the local code of practice or local rules adequate to control the risks identified? Yes/No 
If no, list all additional measures required. 
 
 
Additional Measures: 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance. 
In contact with eyes: 
Rinse thoroughly with plenty of water at least 15minutes and consult a physician. 
In contact with skin: 
Take off contaminated clothes and shoes immediately. Wash off with soap and plenty of water. 
If inhaled: 
If breathed in, move person to fresh air. If not breathing, give artificial respiration. Consult a 
physician.  
If ingested: 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth 
with water. Consult a physician. If experiencing respiratory symptoms: Call a POISON CENTER or 
doctor/  
physician. 
 
Check for damage to leads and cables. Do not operate with wet hands. 
 
 
 
 
 
 
TEMED 
(1,2-
Bis(dimethylamino)ethan) 
1 4 4 
APS 
(Ammonium persulfate) 
1 4 4 
SDS 
(Sodium Dodecyl Sulphate) 
2 3 6 
Methanol 1 4 4 
Glacial acetic acid 1 3 3 
Calcium chloride 
CaCl2 
2 2 4 
15N Labelled ammonium 
chloride 
2 2 4 
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HEALTH SURVEILLANCE ISSUES 
 
Persons at Special 
Risk 
 
Pregnant women 
Health Surveillance 
Measures  
(including symptoms 
and signs of 
exposure) 
Breathing issues, skin rashes, eye irritation, burns to skin. 
 
Exclusions 
 
Potentially pregnant women 
 
 
 
 SIGNATURES 
 
 Staff/PhD student/MSc 
student/Undergraduate 
Name (Print) Signature Date 
Assessor 
 
    
Supervisor 
(if Assessor is a 
student) 
 
    
Local Health and 
Safety Advisor / 
Laboratory 
Manager 
 
    
 
 
